Cat. No.: HY-50895G

Gefitinib (GMP)

(Synonyms: ZD1839 (GMP))

Customer Review

Based on 1 Customer Validation

Gefitinib (ZD1839) (GMP) is Gefitinib (HY-50895) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Gefitinib is a potent, selective and orally active EGFR tyrosine kinase inhibitor.

For research use only. We do not sell to patients.

CAS No.: 184475-35-2
Formula: C₂₂H₂₄ClFN₄O₃
Molecular Weight:446.90

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Gefitinib (GMP) Chemical Structure

CAS No.: 184475-35-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Clinical Trial
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

IC50: 37 nM (Tyr1173 site, in NR6wtEGFR cells), 37 nM (Tyr992 site, in NR6wtEGFR cells)^[1].

All EGFR Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
16HBE14o-	IC₅₀	12.71 μM Compound: gefitinib	Cytotoxicity against human 16HBE14o- cells harboring wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human 16HBE14o- cells harboring wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23668441]
16HBE14o-	IC₅₀	1.601 μM Compound: Gefitinib	Antiproliferative activity against human 16HBE cells expressing wild type EGFR after 72 hrs by MTT assay Antiproliferative activity against human 16HBE cells expressing wild type EGFR after 72 hrs by MTT assay	[PMID: 23792318]
16HBE14o-	IC₅₀	12.71 μM Compound: Iressa	Antiproliferative activity against human 16HBE cells after 72 hrs by MTT assay Antiproliferative activity against human 16HBE cells after 72 hrs by MTT assay	[PMID: 24607591]
A-375	IC₅₀	20.55 μM Compound: Gefitinib	Antiproliferative activity against human A375 cells after 48 hrs by MTT assay Antiproliferative activity against human A375 cells after 48 hrs by MTT assay	[PMID: 20304537]
A-431	IC₅₀	0.023 μM Compound: 29	In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay	[PMID: 11459659]
A-431	IC₅₀	0.276 μg/mL Compound: 1 iressa	Inhibition of A431 cell proliferation Inhibition of A431 cell proliferation	[PMID: 12270171]
A-431	ED₅₀	50 mg/kg Compound: Chemical probe : ZD1839	Antitumor activity against human A-431 cells xenografted in po dosed Swiss nu/nu mouse assessed as tumor growth inhibition administered on day 7 post implantation measured after 3 weeks Antitumor activity against human A-431 cells xenografted in po dosed Swiss nu/nu mouse assessed as tumor growth inhibition administered on day 7 post implantation measured after 3 weeks	[PMID: 12384534]
A-431	IC₅₀	12.05 μM Compound: 1	Cytotoxicity against EGFR overexpressing human A431 cells after 24 hrs by MTT assay Cytotoxicity against EGFR overexpressing human A431 cells after 24 hrs by MTT assay	[PMID: 18771819]
A-431	GI₅₀	0.514 μM Compound: Ire	Growth inhibition of human A431 cells after 72 hrs by MTT assay Growth inhibition of human A431 cells after 72 hrs by MTT assay	[PMID: 19969465]
A-431	IC₅₀	2.15 μM Compound: Gfb	Antiproliferative activity against human A431 cells overexpressing EGFR after 72 hrs by MTS assay Antiproliferative activity against human A431 cells overexpressing EGFR after 72 hrs by MTS assay	[PMID: 22339342]
A-431	IC₅₀	1.08 μM Compound: Gifitinib	Inhibition of EGFR derived from human A431 cell membrane assessed as inhibition of poly-Glu-Tyr phosphorylation after 30 mins by ELISA assay Inhibition of EGFR derived from human A431 cell membrane assessed as inhibition of poly-Glu-Tyr phosphorylation after 30 mins by ELISA assay	[PMID: 22698782]
A-431	IC₅₀	1.41 μM Compound: Gifitinib	Antiproliferative activity against human A431 cells after 48 hrs by MTT assay Antiproliferative activity against human A431 cells after 48 hrs by MTT assay	[PMID: 22698782]
A-431	IC₅₀	4 μM Compound: Gefitinib	Cytotoxicity against human A431 cells incubated for 72 hrs by MTT assay Cytotoxicity against human A431 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
A-431	IC₅₀	4.485 μM Compound: gefitinib	Cytotoxicity against human A431 cells overexpressing wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A431 cells overexpressing wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23668441]
A-431	IC₅₀	8.982 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells expressing wild type EGFR after 72 hrs by MTT assay Antiproliferative activity against human A431 cells expressing wild type EGFR after 72 hrs by MTT assay	[PMID: 23792318]
A-431	IC₅₀	1.1 μM Compound: Gefitinib	Inhibition of EGFR in shed membrane vesicles of human A431 cells using poly-Glu-Tyr as substrate after 30 mins by ELISA Inhibition of EGFR in shed membrane vesicles of human A431 cells using poly-Glu-Tyr as substrate after 30 mins by ELISA	[PMID: 24094432]
A-431	IC₅₀	1.98 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells after 72 hrs by MTT assay Antiproliferative activity against human A431 cells after 72 hrs by MTT assay	[PMID: 24094432]
A-431	IC₅₀	0.55 μM Compound: Gefitinib, Iressa	Cytotoxicity against human A431 cells expressing EGFR after 72 hrs by MTT assay Cytotoxicity against human A431 cells expressing EGFR after 72 hrs by MTT assay	[PMID: 24411123]
A-431	IC₅₀	4.485 μM Compound: Iressa	Antiproliferative activity against human A431 cells overexpressing WT EGFR after 72 hrs by MTT assay Antiproliferative activity against human A431 cells overexpressing WT EGFR after 72 hrs by MTT assay	[PMID: 24607591]
A-431	IC₅₀	4 μM Compound: Gefitinib	Inhibition of wild type EGFR in human A431 cells assessed as growth inhibition after 48 hrs by MTT assay Inhibition of wild type EGFR in human A431 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24900594]
A-431	IC₅₀	4 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells after 48 hrs by Celltiter-Glo assay Antiproliferative activity against human A431 cells after 48 hrs by Celltiter-Glo assay	[PMID: 25409491]
A-431	IC₅₀	3.74 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells after 72 hrs by MTT assay Antiproliferative activity against human A431 cells after 72 hrs by MTT assay	[PMID: 26706113]
A-431	IC₅₀	1.33 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells harboring wild type EGFR assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A431 cells harboring wild type EGFR assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26829280]
A-431	IC₅₀	4.58 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells overexpressing wild-type EGFR after 72 hrs by MTT assay Antiproliferative activity against human A431 cells overexpressing wild-type EGFR after 72 hrs by MTT assay	[PMID: 27387355]
A-431	IC₅₀	0.55 μM Compound: Iressa	Cytotoxicity against human A431 cells overexpressing EGFR assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A431 cells overexpressing EGFR assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27524310]
A-431	IC₅₀	3.308 μM Compound: 1	Antiproliferative activity against wild type human A431 cells after 48 hrs by MTT assay Antiproliferative activity against wild type human A431 cells after 48 hrs by MTT assay	[PMID: 27634676]
A-431	IC₅₀	33 nM Compound: 1	Inhibition of EGFR in human A431 cell membranes preincubated for 30 mins prior to addition of peptide substrate and [gamma32]-ATP measured after 10 mins by scintillation counting method Inhibition of EGFR in human A431 cell membranes preincubated for 30 mins prior to addition of peptide substrate and [gamma32]-ATP measured after 10 mins by scintillation counting method	[PMID: 27769671]
A-431	IC₅₀	12.58 μM Compound: Gefitinib	Antiproliferative activity against EGFR over-expressing human A431 cells after 48 hrs by MTT assay Antiproliferative activity against EGFR over-expressing human A431 cells after 48 hrs by MTT assay	[PMID: 28236592]
A-431	IC₅₀	6.12 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells harboring wild type EGFR assessed as decrease in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A431 cells harboring wild type EGFR assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 28385595]
A-431	IC₅₀	3.3 μM Compound: 1; Iressa	Antiproliferative activity against human A431 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A431 cells incubated for 72 hrs by MTT assay	[PMID: 28395219]
A-431	EC₅₀	2.2 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells harboring wild type EGFR assessed as growth inhibition after 96 hrs by CellTiter-Glo assay Antiproliferative activity against human A431 cells harboring wild type EGFR assessed as growth inhibition after 96 hrs by CellTiter-Glo assay	[PMID: 28603991]
A-431	IC₅₀	4.45 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells harboring wild type EGFR after 72 hrs by MTT assay Antiproliferative activity against human A431 cells harboring wild type EGFR after 72 hrs by MTT assay	[PMID: 28711703]
A-431	EC₅₀	1.71 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells expressing wild type EGFR incubated for 96 hrs measured on day 5 by CellTiterGlo assay Antiproliferative activity against human A431 cells expressing wild type EGFR incubated for 96 hrs measured on day 5 by CellTiterGlo assay	[PMID: 28853575]
A-431	IC₅₀	4.45 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells harboring wild type EGFR after 72 hrs by MTT assay Antiproliferative activity against human A431 cells harboring wild type EGFR after 72 hrs by MTT assay	[PMID: 29421573]
A-431	IC₅₀	768 nM Compound: Gefitinib	Antiproliferative activity against human A431 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo luminescent cell viability assay Antiproliferative activity against human A431 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo luminescent cell viability assay	[PMID: 29523467]
A-431	IC₅₀	1.282 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells harboring wild-type EGFR after 72 hrs by MTT assay Antiproliferative activity against human A431 cells harboring wild-type EGFR after 72 hrs by MTT assay	[PMID: 30471829]
A-431	IC₅₀	2.47 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells after 72 hrs by MTT assay Antiproliferative activity against human A431 cells after 72 hrs by MTT assay	[PMID: 30508379]
A-431	IC₅₀	4.45 μM Compound: ZD1839	Antiproliferative activity against human A431 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A431 cells incubated for 72 hrs by MTT assay	[PMID: 31202990]
A-431	IC₅₀	2.6 μM Compound: 1	Antiproliferative activity against human A-431 cells harboring wild type EGFR assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human A-431 cells harboring wild type EGFR assessed as inhibition of cell growth by MTT assay	[PMID: 31869655]
A-431	IC₅₀	0.55 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells overexpressing EGFR assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human A431 cells overexpressing EGFR assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32139324]
A-431	IC₅₀	2.98 μM Compound: Gefitinib	Antiproliferative activity against human A-431 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human A-431 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32739648]
A-431	IC₅₀	3.308 μM Compound: Gefitinib	Antiproliferative activity against human A-431 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human A-431 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32739648]
A-431	IC₅₀	31.2 μM Compound: IRESSA; ZD1839	Cytotoxicity against human A431 cells measured after 24 hrs by WST-1 assay Cytotoxicity against human A431 cells measured after 24 hrs by WST-1 assay	[PMID: 33260051]
A-431	IC₅₀	8.37 μM Compound: Gefitinib	Antiproliferative activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33640672]
A-431	IC₅₀	16.02 μM Compound: Gefitinib	Antiproliferative activity against human A-431 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human A-431 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34147910]
A-431	IC₅₀	24.55 μM Compound: Gefitinib	Antiproliferative activity against human A-431 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human A-431 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 34147910]
A-431	IC₅₀	32.17 μM Compound: Gefitinib	Antiproliferative activity against human A-431 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Antiproliferative activity against human A-431 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 34147910]
A-431	IC₅₀	1.89 μM Compound: Gefitinib	Cytotoxicity against human A431 cells after 48 hrs by MTT assay Cytotoxicity against human A431 cells after 48 hrs by MTT assay	10.1007/s00044-013-0734-x
A498	IC₅₀	8.6 μM Compound: 1, Iressa	Antiproliferative activity against human A498 cells expressing EGFR and SRC by MTT assay Antiproliferative activity against human A498 cells expressing EGFR and SRC by MTT assay	[PMID: 22818848]
A498	GI₅₀	0.4 μM Compound: Gefitinib	Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
A549	IC₅₀	>10 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring K-ras G12S mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human A549 cells harboring K-ras G12S mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
A549	IC₅₀	13.59 μM Compound: ZD-1839, IRESSA	Cytotoxicity against human A549 cells after 96 hrs by MTT assay Cytotoxicity against human A549 cells after 96 hrs by MTT assay	[PMID: 18313807]
A549	IC₅₀	7 μM Compound: gefitinib	Antiproliferative activity against human A549 cells after 72 hrs by trypan blue exclusion method Antiproliferative activity against human A549 cells after 72 hrs by trypan blue exclusion method	[PMID: 19268405]
A549	IC₅₀	37.93 μM Compound: Gefitinib	Cytotoxicity against human A549 cells after 4 to 5 days by MTT assay Cytotoxicity against human A549 cells after 4 to 5 days by MTT assay	[PMID: 20466555]
A549	IC₅₀	10.08 μM Compound: Gefitinib, Iressa	Antiproliferative activity against human A549 cells overexpressing EGFR gene after 48 hrs by MTT assay Antiproliferative activity against human A549 cells overexpressing EGFR gene after 48 hrs by MTT assay	[PMID: 22119130]
A549	IC₅₀	10.21 μM Compound: Gfb	Antiproliferative activity against human A549 cells expressing wild type EGFR coexpressing k-Ras mutant after 72 hrs by MTS assay Antiproliferative activity against human A549 cells expressing wild type EGFR coexpressing k-Ras mutant after 72 hrs by MTS assay	[PMID: 22339342]
A549	IC₅₀	11.8 μM Compound: Gifitinib	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 22698782]
A549	IC₅₀	15.58 μM Compound: gefitinib	Cytotoxicity against human A549 cells harboring wild type EGFR and k-RAS mutation assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells harboring wild type EGFR and k-RAS mutation assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23668441]
A549	IC₅₀	4.626 μM Compound: Gefitinib	Antiproliferative activity against wild type EGFR/k-Ras dependent human A549 cells after 72 hrs by MTT assay Antiproliferative activity against wild type EGFR/k-Ras dependent human A549 cells after 72 hrs by MTT assay	[PMID: 23792318]
A549	IC₅₀	20.3 μM Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by CCK-8 assay Cytotoxicity against human A549 cells after 72 hrs by CCK-8 assay	[PMID: 23973168]
A549	IC₅₀	39.9 nM Compound: 1, Iressa	Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured at 1 hr by Western blot analysis Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured at 1 hr by Western blot analysis	[PMID: 23988354]
A549	IC₅₀	498 nM Compound: 1, Iressa	Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured after 8 hrs by Western blot analysis Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured after 8 hrs by Western blot analysis	[PMID: 23988354]
A549	IC₅₀	12.92 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 24094432]
A549	IC₅₀	15.58 μM Compound: Iressa	Antiproliferative activity against k-RAS dependent human A549 cells overexpressing WT EGFR after 72 hrs by MTT assay Antiproliferative activity against k-RAS dependent human A549 cells overexpressing WT EGFR after 72 hrs by MTT assay	[PMID: 24607591]
A549	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against human A549 cells after 48 hrs by CellTiter-Glo assay Cytotoxicity against human A549 cells after 48 hrs by CellTiter-Glo assay	[PMID: 24900594]
A549	IC₅₀	11.67 μM Compound: 3	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay	[PMID: 25468044]
A549	IC₅₀	12.17 μM Compound: 3	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay	[PMID: 25468044]
A549	IC₅₀	0.13 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as cell growth by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth by MTT assay	[PMID: 26003342]
A549	IC₅₀	8.4 μM Compound: gefitinib	Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 72 hrs by CellTiter-Glo assay Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 72 hrs by CellTiter-Glo assay	[PMID: 26192023]
A549	IC₅₀	11.02 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
A549	IC₅₀	2.86 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 26346367]
A549	IC₅₀	9.86 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring wild type EGFR/k-Ras mutation after 72 hrs by MTT assay Antiproliferative activity against human A549 cells harboring wild type EGFR/k-Ras mutation after 72 hrs by MTT assay	[PMID: 26451770]
A549	IC₅₀	8.28 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 26560049]
A549	IC₅₀	5.76 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 26706113]
A549	IC₅₀	39.7 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring K-ras mutation assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells harboring K-ras mutation assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26829280]
A549	IC₅₀	9.28 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as viable cells after 48 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as viable cells after 48 hrs by CCK8 assay	[PMID: 26879314]
A549	IC₅₀	24.25 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 27132165]
A549	IC₅₀	13.32 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by cck8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by cck8 assay	[PMID: 27234887]
A549	GI₅₀	7.94 μM Compound: Gefitinib	Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
A549	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27387355]
A549	GI₅₀	2.86 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 48 hrs in presence of 10% FBS by MTT method Antiproliferative activity against human A549 cells after 48 hrs in presence of 10% FBS by MTT method	[PMID: 27515719]
A549	IC₅₀	29.43 μM Compound: 1	Antiproliferative activity against human A549 cells harboring K-ras mutation after 48 hrs by MTT assay Antiproliferative activity against human A549 cells harboring K-ras mutation after 48 hrs by MTT assay	[PMID: 27634676]
A549	IC₅₀	5 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring wild type EGFR after 48 hrs by MTT assay Antiproliferative activity against human A549 cells harboring wild type EGFR after 48 hrs by MTT assay	[PMID: 28236592]
A549	GI₅₀	9.3 μM Compound: Gefitinib	Growth inhibition of human A549 cells after 48 hrs by MTT assay Growth inhibition of human A549 cells after 48 hrs by MTT assay	[PMID: 28291344]
A549	IC₅₀	9.86 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring wild type EGFR after 48 hrs by SRB assay Antiproliferative activity against human A549 cells harboring wild type EGFR after 48 hrs by SRB assay	[PMID: 28366268]
A549	IC₅₀	36.21 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring EGFR K-ras mutant assessed as decrease in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells harboring EGFR K-ras mutant assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 28385595]
A549	IC₅₀	10.07 μM Compound: 1; Iressa	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 28395219]
A549	IC₅₀	22.5 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28462838]
A549	IC₅₀	12.08 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 28711702]
A549	IC₅₀	21.17 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring wild type EGFR/K-Ras mutant after 72 hrs by MTT assay Antiproliferative activity against human A549 cells harboring wild type EGFR/K-Ras mutant after 72 hrs by MTT assay	[PMID: 28711703]
A549	EC₅₀	18.7 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring KRAS-G12S mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay Antiproliferative activity against human A549 cells harboring KRAS-G12S mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay	[PMID: 28853575]
A549	IC₅₀	21.9 μM Compound: Gefitinib	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 28927795]
A549	IC₅₀	8.27 μM Compound: Gefitinib	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 29407971]
A549	IC₅₀	21.17 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring wild type EGFR/K-ras mutant after 72 hrs by MTT assay Antiproliferative activity against human A549 cells harboring wild type EGFR/K-ras mutant after 72 hrs by MTT assay	[PMID: 29421573]
A549	IC₅₀	10.45 μM Compound: Gefitinib	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29496411]
A549	IC₅₀	1260 nM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 29576272]
A549	IC₅₀	10.07 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30471829]
A549	IC₅₀	60 nM Compound: 1	Inhibition of wild type EGFR autophosphorylation in human A549 cells by Western blot analysis Inhibition of wild type EGFR autophosphorylation in human A549 cells by Western blot analysis	[PMID: 30472599]
A549	IC₅₀	2.96 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 30503938]
A549	IC₅₀	11.08 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30508379]
A549	IC₅₀	>10000 nM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring wild-type EGFR after 72 hrs by EZ-Cytox assay Antiproliferative activity against human A549 cells harboring wild-type EGFR after 72 hrs by EZ-Cytox assay	[PMID: 30554954]
A549	IC₅₀	5.74 μM Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 30655941]
A549	IC₅₀	17.9 μM Compound: Iressa(TM)	Antiproliferative activity against human A549 after 18 hrs by MTT assay Antiproliferative activity against human A549 after 18 hrs by MTT assay	[PMID: 30826188]
A549	GI₅₀	7.94 μM Compound: Gefitinib	Growth inhibition of human A549 cells incubated for 48 hrs by SRB assay Growth inhibition of human A549 cells incubated for 48 hrs by SRB assay	[PMID: 31023512]
A549	IC₅₀	21.17 μM Compound: ZD1839	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 31202990]
A549	IC₅₀	2.11 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay	[PMID: 31431361]
A549	IC₅₀	20 μM Compound: Gefitinib	Antiproliferative activity against wild type human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against wild type human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31446247]
A549	IC₅₀	14.803 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 31488358]
A549	IC₅₀	>10 μM Compound: 1	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 31787359]
A549	IC₅₀	10.5 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as cell death Antiproliferative activity against human A549 cells assessed as cell death	[PMID: 32035700]
A549	IC₅₀	15.79 μM Compound: Gefitinib	Growth inhibition of human A549 cells incubated for 5 days by SRB assay Growth inhibition of human A549 cells incubated for 5 days by SRB assay	[PMID: 32145644]
A549	IC₅₀	0.007 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring wild type EGFR assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells harboring wild type EGFR assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32402937]
A549	IC₅₀	2.17 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32739648]
A549	IC₅₀	2.65 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32739648]
A549	IC₅₀	15.59 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33640672]
A549	IC₅₀	3.53 μM Compound: Gefitinib	Cytotoxicity against human A549 cells incubated for 2 to 4 hrs by MTT assay Cytotoxicity against human A549 cells incubated for 2 to 4 hrs by MTT assay	[PMID: 33771586]
A549	IC₅₀	2.69 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells expressing wild type EGFR assessed as inhibition in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells expressing wild type EGFR assessed as inhibition in cell viability after 72 hrs by CCK8 assay	[PMID: 34794818]
A549	IC₅₀	2.64 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells by CCK8 assay Antiproliferative activity against human A549 cells by CCK8 assay	[PMID: 34922028]
A549	IC₅₀	13.26 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells highly expressing EGFR after 48 hrs by MTT assay Antiproliferative activity against human A549 cells highly expressing EGFR after 48 hrs by MTT assay	[PMID: 35247755]
A549	IC₅₀	>50 μM Compound: Gefitinib	Growth inhibition of human A549 cells expressing EGFR incubated for 72 hrs by CCK8 assay Growth inhibition of human A549 cells expressing EGFR incubated for 72 hrs by CCK8 assay	[PMID: 35880853]
A549	IC₅₀	11.28 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by CCK-8 assay	[PMID: 36731272]
A549	IC₅₀	1.43 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay	[PMID: 37875056]
A549	IC₅₀	14.5 μM Compound: Gefitinib	Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 37952262]
A549	IC₅₀	5.44 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38169246]
A549	IC₅₀	6.249 μM Compound: 1	Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK8 assay	[PMID: 38564826]
A549	IC₅₀	5.44 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 38665827]
A549	IC₅₀	8.51 μM Compound: Gefitinib	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	10.1007/s00044-013-0734-x
ASPC1	IC₅₀	6.73 μM Compound: Gefitinib	Antiproliferative activity against human Aspc-1 cells after 72 hrs by MTT assay Antiproliferative activity against human Aspc-1 cells after 72 hrs by MTT assay	[PMID: 30471829]
B16-F10	IC₅₀	2.2 μM Compound: Gefitinib	Antiproliferative activity against mouse B16F10 cells after 24 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 24 hrs by MTT assay	[PMID: 25866240]
B16-F10	ED₅₀	0.91 μg/mL Compound: Gefitinib	Cytotoxicity against Homo sapiens (human) B16F10 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) B16F10 cells after 72 hr by MTT assay	10.1007/s00044-012-0309-2
BaF3	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR Del E746_S752InsV/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR Del E746_S752InsV/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR Del L747_A750InsP/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR Del L747_A750InsP/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR Del L747_P753InsS/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR Del L747_P753InsS/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR Del S752_I759/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR Del S752_I759/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR L858R/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR L858R/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	2.7 μM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR vIII mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR vIII mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	26 nM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR L858R mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR L858R mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	3.1 μM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR A767_V769duspASV mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR A767_V769duspASV mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	306 nM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR Del E746_S752InsV mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR Del E746_S752InsV mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	35 nM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR Del S752_I759 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR Del S752_I759 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	4.1 nM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR Del L747_P753InsS mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR Del L747_P753InsS mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	4.8 nM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR Del E746_A750 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR Del E746_A750 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	7.4 nM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR Del L747_A750InsP mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR Del L747_A750InsP mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	8.3 μM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells harboring EGFR Del E746_A750/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Cytotoxicity against mouse BaF3 cells harboring EGFR Del E746_A750/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
BaF3	IC₅₀	10.8 nM Compound: gefitinib	Cytotoxicity against mouse BA/F3 cells expressing EGFR L858R mutant Cytotoxicity against mouse BA/F3 cells expressing EGFR L858R mutant	[PMID: 19239229]
BaF3	IC₅₀	>3.3 μM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring EGFR A767_V769dupASV mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring EGFR A767_V769dupASV mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
BaF3	IC₅₀	>3.3 μM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring EGFR E746_A750/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring EGFR E746_A750/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
BaF3	IC₅₀	>3.3 μM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring EGFR E746_A750/T790M/C797S mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring EGFR E746_A750/T790M/C797S mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
BaF3	IC₅₀	>3.3 μM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring EGFR L858R/T790M double mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring EGFR L858R/T790M double mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
BaF3	IC₅₀	>3.3 μM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring EGFR L858R/T790M/C797S triple mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring EGFR L858R/T790M/C797S triple mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
BaF3	IC₅₀	1.9 μM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring ERBB2 Ins G776V,C mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring ERBB2 Ins G776V,C mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
BaF3	IC₅₀	2 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring EGFR E746_A750 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring EGFR E746_A750 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
BaF3	IC₅₀	2.3 μM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring ERBB2 Ins 774YVMA mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring ERBB2 Ins 774YVMA mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
BaF3	IC₅₀	3 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring EGFR L858R mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring EGFR L858R mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
BaF3	IC₅₀	454 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring EGFR vIII mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring EGFR vIII mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
BaF3	IC₅₀	760 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring wildtype ERBB2 assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against mouse BaF3 cells harboring wildtype ERBB2 assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
BaF3	IC₅₀	>10000 nM Compound: Gefitinib	Cytotoxicity against mouse BaF3 cells expressing IL-3 assessed as inhibition of cell viability incubated for 72 hrs by CellTiter-Glo assay Cytotoxicity against mouse BaF3 cells expressing IL-3 assessed as inhibition of cell viability incubated for 72 hrs by CellTiter-Glo assay	[PMID: 28287083]
BaF3	IC₅₀	10.6 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells expressing Del19 assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay Antiproliferative activity against mouse BaF3 cells expressing Del19 assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay	[PMID: 36384036]
BaF3	IC₅₀	12.5 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells expressing De119/C797S assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay Antiproliferative activity against mouse BaF3 cells expressing De119/C797S assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay	[PMID: 36384036]
BaF3	IC₅₀	1757 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells expressing Ex20 insertion GV mutant assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay Antiproliferative activity against mouse BaF3 cells expressing Ex20 insertion GV mutant assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay	[PMID: 36384036]
BaF3	IC₅₀	21.8 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells expressing L858R assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay Antiproliferative activity against mouse BaF3 cells expressing L858R assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay	[PMID: 36384036]
BaF3	IC₅₀	2779.2 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells expressing Ex20 insertion NPG mutant assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay Antiproliferative activity against mouse BaF3 cells expressing Ex20 insertion NPG mutant assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay	[PMID: 36384036]
BaF3	IC₅₀	53.6 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells expressing EGFR WT assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay Antiproliferative activity against mouse BaF3 cells expressing EGFR WT assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay	[PMID: 36384036]
BaF3	IC₅₀	54.2 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells expressing L858R/C797S assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay Antiproliferative activity against mouse BaF3 cells expressing L858R/C797S assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay	[PMID: 36384036]
BaF3	IC₅₀	6981.5 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells expressing Ex20 insertion SVD mutant assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay Antiproliferative activity against mouse BaF3 cells expressing Ex20 insertion SVD mutant assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay	[PMID: 36384036]
BaF3	IC₅₀	2500 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring EGFR-D770-N771insNPG mutant incubated for 3 days by Cell Titer-Glo assay Antiproliferative activity against mouse BaF3 cells harboring EGFR-D770-N771insNPG mutant incubated for 3 days by Cell Titer-Glo assay	[PMID: 37669428]
BaF3	IC₅₀	55.5 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring wild type EGFR incubated for 3 days by Cell Titer-Glo assay Antiproliferative activity against mouse BaF3 cells harboring wild type EGFR incubated for 3 days by Cell Titer-Glo assay	[PMID: 37669428]
BaF3	IC₅₀	19.96 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells harboring EGFR D770_N771insSVD by CellTiter-Glo assay Antiproliferative activity against mouse BaF3 cells harboring EGFR D770_N771insSVD by CellTiter-Glo assay	[PMID: 38518121]
BEAS-2B	IC₅₀	13.94 μM Compound: gefitinib	Cytotoxicity against human BEAS2B cells harboring wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human BEAS2B cells harboring wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23668441]
BEAS-2B	IC₅₀	13.94 μM Compound: Iressa	Antiproliferative activity against human BEAS2B cells after 72 hrs by MTT assay Antiproliferative activity against human BEAS2B cells after 72 hrs by MTT assay	[PMID: 24607591]
Bel-7402	IC₅₀	11.21 μM Compound: Gef	Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32827851]
BT-474	EC₅₀	300 nM Compound: Iressa	Antiproliferative activity against human BT474 cells overexpressing ERBb2 after 3 days by methylene blue staining Antiproliferative activity against human BT474 cells overexpressing ERBb2 after 3 days by methylene blue staining	[PMID: 19028424]
BT-474	IC₅₀	0.36 μM Compound: Gefitinib, Iressa	Cytotoxicity against human BT474 cells expressing HER2 after 72 hrs by MTT assay Cytotoxicity against human BT474 cells expressing HER2 after 72 hrs by MTT assay	[PMID: 24411123]
BT-474	IC₅₀	0.53 μM Compound: Gefitinib	Antiproliferative activity against human BT474 cells after 72 hrs by MTT assay Antiproliferative activity against human BT474 cells after 72 hrs by MTT assay	[PMID: 27132165]
BT-474	IC₅₀	1.24 μM Compound: Gefitinib	Cytotoxicity against human BT474 cells expressing Her2 assessed as reduction in cell viability after 72 hrs by cell titer-glo luminescence assay Cytotoxicity against human BT474 cells expressing Her2 assessed as reduction in cell viability after 72 hrs by cell titer-glo luminescence assay	[PMID: 27288180]
BT-474	IC₅₀	0.36 μM Compound: Iressa	Cytotoxicity against human BT474 cells overexpressing HER2 assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human BT474 cells overexpressing HER2 assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27524310]
BT-474	IC₅₀	0.365 μM Compound: Gefitinib	Antiproliferative activity against human BT474 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human BT474 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32139324]
BT-549	IC₅₀	6.56 μM Compound: Gefitinib	Cytotoxicity against human BT549 cells after 72 hrs by SRB assay Cytotoxicity against human BT549 cells after 72 hrs by SRB assay	[PMID: 29407971]
BT-549	IC₅₀	6.76 μM Compound: Gefitinib	Cytotoxicity against human BT-549 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human BT-549 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36610250]
Calu-3	IC₅₀	1.4 μM Compound: Gefitinib	Antiproliferative activity against human Calu-3 cells overexpressing ERBB2 assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human Calu-3 cells overexpressing ERBB2 assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
Calu-3	IC₅₀	2.7 μM Compound: Gefitinib	Antiproliferative activity against human Calu-3 cells harboring ERBB2 amp mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human Calu-3 cells harboring ERBB2 amp mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
Calu-3	IC₅₀	1.6 μM Compound: Gefitinib	Cytotoxicity against human Calu3 cells incubated for 72 hrs by MTT assay Cytotoxicity against human Calu3 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
Calu-3	IC₅₀	0.99 μM Compound: Gefitinib, Iressa	Cytotoxicity against human Calu3 cells expressing HER2 after 72 hrs by MTT assay Cytotoxicity against human Calu3 cells expressing HER2 after 72 hrs by MTT assay	[PMID: 24411123]
Calu-3	IC₅₀	0.985 μM Compound: Gefitinib	Antiproliferative activity against human Calu3 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human Calu3 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32139324]
Calu-3	IC₅₀	4.52 μM Compound: Gefitinib	Antiproliferative activity against human Calu-3 cells by CCK8 assay Antiproliferative activity against human Calu-3 cells by CCK8 assay	[PMID: 34922028]
CCRF-CEM	GI₅₀	5.01 μM Compound: Gefitinib	Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
CCRF-CEM	GI₅₀	5.01 μM Compound: Gefitinib	Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by SRB assay Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by SRB assay	[PMID: 31023512]
CHO-K1	GI₅₀	43.7 μM Compound: Gefitinib	Growth inhibition of CHOK1 cells after 48 hrs by MTT assay Growth inhibition of CHOK1 cells after 48 hrs by MTT assay	[PMID: 28291344]
CL97	IC₅₀	10 μM Compound: Gefitinib	Antiproliferative activity against human CL97 cells harbouring EGFR G719A/T790M mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human CL97 cells harbouring EGFR G719A/T790M mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31446247]
CNE	IC₅₀	23.5 μM Compound: Gefitinib	Antiproliferative activity against human CNE cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human CNE cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32739648]
CWR22R	IC₅₀	14 μM Compound: Gefitinib	Growth inhibition of human 22Rv1 cells after 5 days by SRB assay Growth inhibition of human 22Rv1 cells after 5 days by SRB assay	[PMID: 32484346]
DU-145	IC₅₀	42.17 μM Compound: Gefitinib	Cytotoxicity against human DU145 cells after 4 to 5 days by MTT assay Cytotoxicity against human DU145 cells after 4 to 5 days by MTT assay	[PMID: 20466555]
DU-145	IC₅₀	>100 μM Compound: 2	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 23871909]
DU-145	IC₅₀	8.63 μM Compound: Gefitinib	Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay	[PMID: 28711702]
DU-145	IC₅₀	>100 μM Compound: Gefitinib	Antiproliferative activity against human DU145 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human DU145 cells incubated for 72 hrs by MTT assay	[PMID: 31488358]
DU-145	IC₅₀	7.3 μM Compound: Gefitinib	Growth inhibition of human DU145 cells after 5 days by SRB assay Growth inhibition of human DU145 cells after 5 days by SRB assay	[PMID: 32484346]
ECa-109 cell line	IC₅₀	26.47 μM Compound: Gefitinib	Cytotoxicity against human ECa-109 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human ECa-109 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32866757]
FaDu	IC₅₀	0.05 μM Compound: Gefitinib	Cytotoxicity against human FADU cells incubated for 72 hrs by MTT assay Cytotoxicity against human FADU cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
H322	IC₅₀	>10 μM Compound: Gefitinib	Antiproliferative activity against human H322 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human H322 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
HCC4006	IC₅₀	0.05 μM Compound: Gefitinib	Antiproliferative activity against human HCC4006 cells harboring EGFR Del L747_E749 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human HCC4006 cells harboring EGFR Del L747_E749 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
HCC827	IC₅₀	0.004 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant transfected with GFP assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant transfected with GFP assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
HCC827	IC₅₀	0.008 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
HCC827	IC₅₀	0.008 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant transfected with EGFR WT/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant transfected with EGFR WT/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
HCC827	IC₅₀	0.026 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant transfected with ERBB2 assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant transfected with ERBB2 assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
HCC827	IC₅₀	0.927 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant transfected with EGFR L858R/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant transfected with EGFR L858R/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
HCC827	IC₅₀	1.93 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant transfected with EGFR Del L747_S752,P753S/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant transfected with EGFR Del L747_S752,P753S/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
HCC827	IC₅₀	4.82 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant transfected with ERBB2 Ins 774YVMA assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant transfected with ERBB2 Ins 774YVMA assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
HCC827	IC₅₀	8 nM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human HCC827 cells harboring EGFR Del E746_A750 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
HCC827	IC₅₀	12 nM Compound: gefitinib	Antiproliferative activity against human HCC827 cells after 96 hrs by MTS assay Antiproliferative activity against human HCC827 cells after 96 hrs by MTS assay	[PMID: 20550212]
HCC827	IC₅₀	0.013 μM Compound: 1, ZD-1839	Antiproliferative activity against human HCC827 cells by MTS assay Antiproliferative activity against human HCC827 cells by MTS assay	[PMID: 20961149]
HCC827	IC₅₀	0.008 μM Compound: Gfb	Antiproliferative activity against human HCC827 cells harboring EGFR del E746-A750 mutant after 72 hrs by MTS assay Antiproliferative activity against human HCC827 cells harboring EGFR del E746-A750 mutant after 72 hrs by MTS assay	[PMID: 22339342]
HCC827	IC₅₀	0.0015 μM Compound: Gefitinib	Cytotoxicity against human HCC827 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HCC827 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
HCC827	IC₅₀	0.006 μM Compound: gefitinib	Cytotoxicity against gefitinib-sensitive human HCC827 cells harboring EGFR E746_A740 deletion mutant assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against gefitinib-sensitive human HCC827 cells harboring EGFR E746_A740 deletion mutant assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23668441]
HCC827	IC₅₀	0.006 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells expressing EGFR E746_A750 deletion mutant after 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells expressing EGFR E746_A750 deletion mutant after 72 hrs by MTT assay	[PMID: 23792318]
HCC827	IC₅₀	0.012 μM Compound: 1	Cytotoxicity against human HCC827 cells after 72 hrs by CCK-8 assay Cytotoxicity against human HCC827 cells after 72 hrs by CCK-8 assay	[PMID: 23973168]
HCC827	IC₅₀	5.81 nM Compound: Gefitinib	Antiproliferative activity against gefitinib-sensitive human HCC827 cells harboring EGFR E746 to A750 deletion after 72 hrs by MTS assay Antiproliferative activity against gefitinib-sensitive human HCC827 cells harboring EGFR E746 to A750 deletion after 72 hrs by MTS assay	[PMID: 24053674]
HCC827	IC₅₀	0.006 μM Compound: Iressa	Antiproliferative activity against gefitinib-sensitive human HCC827 cells bearing EGFR del E746_A750 mutant after 72 hrs by MTT assay Antiproliferative activity against gefitinib-sensitive human HCC827 cells bearing EGFR del E746_A750 mutant after 72 hrs by MTT assay	[PMID: 24607591]
HCC827	IC₅₀	33 nM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells after 48 hrs by MTT assay Antiproliferative activity against human HCC827 cells after 48 hrs by MTT assay	[PMID: 25937236]
HCC827	IC₅₀	0.013 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR E746 to A750 deletion mutant assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells harboring EGFR E746 to A750 deletion mutant assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26829280]
HCC827	IC₅₀	0.002 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR E746_A750 deletion mutant after 48 hrs by MTT assay Antiproliferative activity against human HCC827 cells harboring EGFR E746_A750 deletion mutant after 48 hrs by MTT assay	[PMID: 28236592]
HCC827	IC₅₀	0.0099 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR del E746 to A750 mutant assessed as decrease in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells harboring EGFR del E746 to A750 mutant assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 28385595]
HCC827	IC₅₀	0.006 μM Compound: 1; Iressa	Antiproliferative activity against human HCC827 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells incubated for 72 hrs by MTT assay	[PMID: 28395219]
HCC827	EC₅₀	<0.014 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR-delE746_A750 mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay Antiproliferative activity against human HCC827 cells harboring EGFR-delE746_A750 mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay	[PMID: 28853575]
HCC827	IC₅₀	1.6 nM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR E746-A750 del mutant after 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells harboring EGFR E746-A750 del mutant after 72 hrs by MTT assay	[PMID: 29421573]
HCC827	IC₅₀	33.3 nM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay	[PMID: 29576272]
HCC827	IC₅₀	0.16 x 10^-2 μM Compound: ZD1839	Antiproliferative activity against human HCC827 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells incubated for 72 hrs by MTT assay	[PMID: 31202990]
HCC827	CC₅₀	26 nM Compound: Gefitinib	Cytotoxicity in human HCC827 cells assessed as reduction in cell viability incubated for 96 hrs by MTS method Cytotoxicity in human HCC827 cells assessed as reduction in cell viability incubated for 96 hrs by MTS method	[PMID: 31560541]
HCC827	IC₅₀	0.01 μM Compound: 1	Antiproliferative activity against human HCC827 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells incubated for 72 hrs by MTT assay	[PMID: 31787359]
HCC827	IC₅₀	0.006 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32739648]
HCC827	IC₅₀	0.00169 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells expressing EGFR del119 mutant assessed as inhibition in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human HCC827 cells expressing EGFR del119 mutant assessed as inhibition in cell viability after 72 hrs by CCK8 assay	[PMID: 34794818]
HCC827	IC₅₀	64 nM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells expressing EGFR del19 mutant assessed as inhibition of cell growth Antiproliferative activity against human HCC827 cells expressing EGFR del19 mutant assessed as inhibition of cell growth	[PMID: 35728507]
HCC827	IC₅₀	9.08 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells assessed as inhibition of cell growth incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human HCC827 cells assessed as inhibition of cell growth incubated for 24 hrs by CCK-8 assay	[PMID: 36731272]
HCC827	IC₅₀	7.3 nM Compound: 1	Antiproliferative activity against human HCC827 cells harboring EGFR del E746_A750 mutant assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo luminescent assay Antiproliferative activity against human HCC827 cells harboring EGFR del E746_A750 mutant assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo luminescent assay	[PMID: 37934858]
HCC827	IC₅₀	0.23 nM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells by CellTiter-Glo assay Antiproliferative activity against human HCC827 cells by CellTiter-Glo assay	[PMID: 38518121]
HCC827	IC₅₀	0.019 μM Compound: 1	Antiproliferative activity against human HCC827 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HCC827 cells incubated for 72 hrs by CCK8 assay	[PMID: 38564826]
HCC827	IC₅₀	0.041 μM Compound: Gefitinib	Cytotoxicity against human HCC827 cells expressing EGFR kinase E746 to A750 deletion mutant after 72 hrs by MTS assay Cytotoxicity against human HCC827 cells expressing EGFR kinase E746 to A750 deletion mutant after 72 hrs by MTS assay	10.1039/C2MD20078C
HCT-116	IC₅₀	66.9 μM Compound: GF	Induction of apoptosis in human HCT116 cells expressing KRAS mutant assessed as depolarization of mitochondrial membrane after 24 hrs by flow cytometry Induction of apoptosis in human HCT116 cells expressing KRAS mutant assessed as depolarization of mitochondrial membrane after 24 hrs by flow cytometry	[PMID: 23063521]
HCT-116	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
HCT-116	GI₅₀	7.94 μM Compound: Gefitinib	Growth inhibition of human HCT-116 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCT-116 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
HCT-116	IC₅₀	5.98 μM Compound: Gefitinib	Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 29407971]
HCT-116	IC₅₀	21.55 μM Compound: Iressa(TM)	Antiproliferative activity against human HCT116 after 18 hrs by MTT assay Antiproliferative activity against human HCT116 after 18 hrs by MTT assay	[PMID: 30826188]
HCT-116	IC₅₀	19.82 μM Compound: Gefitinib	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell viability after 48 hrs by MTS assay Antiproliferative activity against human HCT116 cells assessed as inhibition of cell viability after 48 hrs by MTS assay	[PMID: 31494469]
HCT-116	IC₅₀	1.43 μM Compound: Gefitinib	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay	[PMID: 37875056]
HCT-116	IC₅₀	6.46 μM Compound: Gefitinib	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38169246]
HCT-15	GI₅₀	5.01 μM Compound: Gefitinib	Growth inhibition of human HCT-15 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCT-15 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
HEK293	IC₅₀	420 nM Compound: Gefitinib	Inhibition of tracer 5 binding to human N-terminal nano luciferase-fused GAK expressed in HEK293 cells measured after 2 hrs by nanoBRET assay Inhibition of tracer 5 binding to human N-terminal nano luciferase-fused GAK expressed in HEK293 cells measured after 2 hrs by nanoBRET assay	[PMID: 30973735]
HEK-293T	CC₅₀	52.03 μM Compound: Gefitinib	Cytotoxicity against human 293T cells after 24 hrs by MTT assay Cytotoxicity against human 293T cells after 24 hrs by MTT assay	[PMID: 25866240]
HEK-293T	IC₅₀	84.87 μM Compound: Gefitinib	Cytotoxicity against HEK293T cells assessed as inhibition of cell growth incubated for 24 hrs by CCK-8 assay Cytotoxicity against HEK293T cells assessed as inhibition of cell growth incubated for 24 hrs by CCK-8 assay	[PMID: 36731272]
HeLa	IC₅₀	45.59 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 20304537]
HeLa	IC₅₀	108.3 μM Compound: GF	Induction of apoptosis in human HeLa cells expressing wild type KRAS and BRAF assessed as depolarization of mitochondrial membrane after 24 hrs by flow cytometry Induction of apoptosis in human HeLa cells expressing wild type KRAS and BRAF assessed as depolarization of mitochondrial membrane after 24 hrs by flow cytometry	[PMID: 23063521]
HeLa	IC₅₀	2.67 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells assessed as growth inhibition after 24 to 48 hrs by CCK8 assay Antiproliferative activity against human HeLa cells assessed as growth inhibition after 24 to 48 hrs by CCK8 assay	[PMID: 24731281]
HeLa	IC₅₀	2.26 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay	[PMID: 25866240]
HeLa	IC₅₀	15.4 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
HeLa	IC₅₀	1.52 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay	[PMID: 26346367]
HeLa	GI₅₀	1.52 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells after 48 hrs in presence of 10% FBS by MTT method Antiproliferative activity against human HeLa cells after 48 hrs in presence of 10% FBS by MTT method	[PMID: 27515719]
HeLa	IC₅₀	18.3 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28462838]
HeLa	IC₅₀	9.68 μM Compound: Gefitinib	Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay	[PMID: 29624387]
HeLa	IC₅₀	4.3 μM Compound: Gefitinib	Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 29656203]
HeLa	IC₅₀	1.48 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30342958]
HeLa	IC₅₀	23.92 μM Compound: Gefitinib	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32866757]
HeLa	IC₅₀	39.32 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells by CCK8 assay Antiproliferative activity against human HeLa cells by CCK8 assay	[PMID: 34922028]
HEp-2	CC₅₀	>100 μM Compound: 24	Cytotoxicity against human HEp-2 cells Cytotoxicity against human HEp-2 cells	[PMID: 33539089]
HepG2	IC₅₀	6.42 μM Compound: Iressa	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 22727449]
HepG2	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
HepG2	IC₅₀	29.79 μM Compound: 2	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 23871909]
HepG2	IC₅₀	6.42 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells assessed as growth inhibition after 24 to 48 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells assessed as growth inhibition after 24 to 48 hrs by CCK8 assay	[PMID: 24731281]
HepG2	IC₅₀	0.12 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells assessed as cell growth by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell growth by MTT assay	[PMID: 26003342]
HepG2	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 26159483]
HepG2	IC₅₀	18.22 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 26560049]
HepG2	IC₅₀	7.52 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells over expressing EGFR after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells over expressing EGFR after 48 hrs by MTT assay	[PMID: 27118497]
HepG2	IC₅₀	>50 μM Compound: Gefitinib	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27387355]
HepG2	IC₅₀	15.9 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 28462838]
HepG2	IC₅₀	29.79 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 28711702]
HepG2	IC₅₀	18.36 μM Compound: Iressa(TM)	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 30826188]
HepG2	IC₅₀	6.6 μM Compound: Gefitinib	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 31013087]
HepG2	IC₅₀	29.79 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay	[PMID: 31488358]
HepG2	IC₅₀	33.9 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32739648]
HepG2	IC₅₀	24.19 μM Compound: Gefitinib	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32866757]
HepG2	IC₅₀	>10 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells Antiproliferative activity against human HepG2 cells	[PMID: 33421712]
HepG2	IC₅₀	1.43 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay	[PMID: 37875056]
HepG2	IC₅₀	16.1 μM Compound: Gefitinib	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 38784474]
HGC-27	IC₅₀	12.44 μM Compound: Gefitinib	Cytotoxicity against human HGC27 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HGC27 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30939352]
HL-60	IC₅₀	54.5 μM Compound: Gifitinib	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 22698782]
HN5	EC₅₀	10 nM Compound: Iressa	Antiproliferative activity against human HN5 cells overexpressing EGFR after 3 days by methylene blue staining Antiproliferative activity against human HN5 cells overexpressing EGFR after 3 days by methylene blue staining	[PMID: 19028424]
HOP-62	GI₅₀	10 μM Compound: Gefitinib	Growth inhibition of human HOP-62 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HOP-62 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
HOP-92	GI₅₀	7.94 μM Compound: Gefitinib	Growth inhibition of human HOP-92 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HOP-92 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Hs-578T	GI₅₀	10 μM Compound: Gefitinib	Growth inhibition of human Hs-578T cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Hs-578T cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Hs-578T	IC₅₀	17.22 μM Compound: Gefitinib	Cytotoxicity against human Hs-578T cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human Hs-578T cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36610250]
HT-29	IC₅₀	9.8 μM Compound: Iressa	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 20056425]
HT-29	IC₅₀	16.93 μM Compound: Gefitinib	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 20304537]
HT-29	IC₅₀	3.36 μM Compound: Iressa	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 22727449]
HT-29	IC₅₀	110.3 μM Compound: GF	Induction of apoptosis in human HT-29 cells expressing BRAF mutant assessed as depolarization of mitochondrial membrane after 24 hrs by flow cytometry Induction of apoptosis in human HT-29 cells expressing BRAF mutant assessed as depolarization of mitochondrial membrane after 24 hrs by flow cytometry	[PMID: 23063521]
HT-29	IC₅₀	3.63 μM Compound: Gefitinib	Cytotoxicity against human HT-29 cells after 72 hrs under normoxia conditions by SRB assay Cytotoxicity against human HT-29 cells after 72 hrs under normoxia conditions by SRB assay	[PMID: 25462282]
HT-29	IC₅₀	5.21 μM Compound: Gefitinib	Cytotoxicity against human HT-29 cells after 72 hrs under hypoxia conditions by SRB assay Cytotoxicity against human HT-29 cells after 72 hrs under hypoxia conditions by SRB assay	[PMID: 25462282]
HT-29	IC₅₀	3.63 μM Compound: 3	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay	[PMID: 25468044]
HT-29	IC₅₀	5.21 μM Compound: 3	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay	[PMID: 25468044]
HT-29	IC₅₀	8.19 μM Compound: Gefitinib	Cytotoxicity against human HT-29 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 26451770]
HT-29	GI₅₀	3.98 μM Compound: Gefitinib	Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
HT-29	IC₅₀	8.19 μM Compound: Gefitinib	Antiproliferative activity against non-special gene type human HT-29 cells after 48 hrs by SRB assay Antiproliferative activity against non-special gene type human HT-29 cells after 48 hrs by SRB assay	[PMID: 28366268]
Huh-7	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against human HuH7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human HuH7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 26159483]
Huh-7	IC₅₀	>10 μM Compound: Gefitinib	Antiproliferative activity against human Huh-7 cells Antiproliferative activity against human Huh-7 cells	[PMID: 33421712]
HuTu80	ED₅₀	0.77 μg/mL Compound: Gefitinib	Cytotoxicity against Homo sapiens (human) HuTu 80 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) HuTu 80 cells after 72 hr by MTT assay	10.1007/s00044-012-0309-2
HUVEC	IC₅₀	0.03 μM Compound: Chemical probe : ZD1839	Antiproliferative activity against EGF stimulated HUVEC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against EGF stimulated HUVEC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 12384534]
HUVEC	IC₅₀	1 μM Compound: Chemical probe : ZD1839	Antiproliferative activity against FGF stimulated HUVEC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against FGF stimulated HUVEC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 12384534]
HUVEC	IC₅₀	1 μM Compound: Chemical probe : ZD1839	Antiproliferative activity against VEGF stimulated HUVEC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against VEGF stimulated HUVEC cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 12384534]
HUVEC	GI₅₀	13 μM Compound: Gefitinib	Growth inhibition of HUVEC after 48 hrs by MTT assay Growth inhibition of HUVEC after 48 hrs by MTT assay	[PMID: 28291344]
IGROV-1	GI₅₀	0.2 μM Compound: Gefitinib	Growth inhibition of human IGROV-1 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human IGROV-1 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
K562	IC₅₀	9.36 μM Compound: ZD-1839, IRESSA	Cytotoxicity against human K562 cells after 96 hrs by MTT assay Cytotoxicity against human K562 cells after 96 hrs by MTT assay	[PMID: 18313807]
K562	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against human K562 cells after 48 hrs by CellTiter-Glo assay Cytotoxicity against human K562 cells after 48 hrs by CellTiter-Glo assay	[PMID: 24900594]
K562	GI₅₀	2.51 μM Compound: Gefitinib	Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
K562	IC₅₀	14.27 μM Compound: Gefitinib	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 35247755]
K562/A02	IC₅₀	32.35 μM Compound: Gefitinib	Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay	[PMID: 35247755]
KB	IC₅₀	0.054 μM Compound: Chemical probe : ZD1839	Antiproliferative activity against EGF stimulated human KB cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against EGF stimulated human KB cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 12384534]
KB	IC₅₀	8.8 μM Compound: Chemical probe : ZD1839	Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 12384534]
KB	IC₅₀	0.054 μM Compound: Iressa	Antiproliferative activity against EGF-stimulated human KB cell line Antiproliferative activity against EGF-stimulated human KB cell line	[PMID: 16516473]
KB	IC₅₀	80 nM Compound: 1	Antiproliferative activity against EGF-stimulated KB cells Antiproliferative activity against EGF-stimulated KB cells	[PMID: 16806916]
KB	IC₅₀	2.8 μM Compound: 1, Iressa	Antiproliferative activity against human KB cells expressing EGFR and SRC by MTT assay Antiproliferative activity against human KB cells expressing EGFR and SRC by MTT assay	[PMID: 22818848]
KB	IC₅₀	0.025 μM Compound: Gefitinib, Iressa	Inhibition of EGF-stimulated autophosphorylation of EGFR in human KB cells incubated for 1 hr prior to EGF challenge measured after 6 mins by ELISA Inhibition of EGF-stimulated autophosphorylation of EGFR in human KB cells incubated for 1 hr prior to EGF challenge measured after 6 mins by ELISA	[PMID: 24411123]
KB	IC₅₀	0.025 μM Compound: Gefitinib	Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA	[PMID: 32139324]
KB	IC₅₀	54 nM Compound: 1	Antiproliferative activity against EGF-stimulated human KB cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against EGF-stimulated human KB cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 33540357]
KB	ED₅₀	0.33 μg/mL Compound: Gefitinib	Cytotoxicity against Homo sapiens (human) KB cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) KB cells after 72 hr by MTT assay	10.1007/s00044-012-0309-2
KB 3-1	IC₅₀	0.08 μM Compound: 29	In vitro inhibitory activity against EGF-stimulated proliferation of KB2 cells in culture In vitro inhibitory activity against EGF-stimulated proliferation of KB2 cells in culture	[PMID: 11459659]
KM12	GI₅₀	7.94 μM Compound: Gefitinib	Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
L02	IC₅₀	>10 μM Compound: Gfb	Antiproliferative activity against human HL7702 cells expressing wilt type EGFR after 72 hrs by MTS assay Antiproliferative activity against human HL7702 cells expressing wilt type EGFR after 72 hrs by MTS assay	[PMID: 22339342]
L02	IC₅₀	19.8 μM Compound: Gefitinib	Cytotoxicity against human LO2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human LO2 cells assessed as reduction in cell viability by MTT assay	[PMID: 31013087]
L02	IC₅₀	7.14 μM Compound: Gefitinib	Cytotoxicity against human L0-2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human L0-2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32402937]
L02	IC₅₀	13.26 μM Compound: Gefitinib	Cytotoxicity against human HL7702 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32866757]
L02	IC₅₀	33.17 μM Compound: Gefitinib	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33640672]
L02	IC₅₀	10.08 μM Compound: 4	Cytotoxicity against human L02 cells assessed as inhibition of cell growth measured by CCK8 assay Cytotoxicity against human L02 cells assessed as inhibition of cell growth measured by CCK8 assay	[PMID: 34216747]
L02	IC₅₀	45.31 μM Compound: Gefitinib	Cytotoxicity against human L02 cells by CCK8 assay Cytotoxicity against human L02 cells by CCK8 assay	[PMID: 34922028]
L02	IC₅₀	55.08 μM Compound: Gefitinib	Cytotoxicity against human HL7702 cells expressing wild type EGFR after 72 hrs by MTS assay Cytotoxicity against human HL7702 cells expressing wild type EGFR after 72 hrs by MTS assay	10.1039/C2MD20078C
L132	ED₅₀	>1 μg/mL Compound: Gefitinib	Cytotoxicity against Homo sapiens (human) L-132 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) L-132 cells after 72 hr by MTT assay	10.1007/s00044-012-0309-2
L929	IC₅₀	1.98 μM Compound: Gefitinib	Cytotoxicity against mouse L929 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against mouse L929 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 30508379]
LoVo	IC₅₀	0.062 μM Compound: 1	Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay	[PMID: 23930994]
LoVo	IC₅₀	59 nM Compound: 10	Growth inhibition of human LoVo cells harboring wild type EGFR Growth inhibition of human LoVo cells harboring wild type EGFR	[PMID: 32432477]
LOX IMVI	GI₅₀	7.94 μM Compound: Gefitinib	Growth inhibition of human LOX IMVI cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human LOX IMVI cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Macrophage	CC₅₀	280.6 μM Compound: Gefitinib	Antiproliferative activity against human macrophages assessed as alteration in cell morphology after 24 hrs by CCK8 assay Antiproliferative activity against human macrophages assessed as alteration in cell morphology after 24 hrs by CCK8 assay	[PMID: 24731281]
MCF-10A	IC₅₀	30 μM Compound: Gefitinib	Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay	[PMID: 25198997]
MCF-10A	IC₅₀	20.54 μM Compound: Gefitinib	Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36610250]
MCF7	IC₅₀	1 μM Compound: 1	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 18771819]
MCF7	IC₅₀	1.1 μM Compound: Gefitinib	Inhibition of BCRP expressed in MCF7 MX cells by Hoechst 33342 staining Inhibition of BCRP expressed in MCF7 MX cells by Hoechst 33342 staining	[PMID: 19932960]
MCF7	IC₅₀	69.16 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 20304537]
MCF7	IC₅₀	12.05 μM Compound: Gefitinib, Iressa	Antiproliferative activity against human MCF7 cells overexpressing EGFR gene after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells overexpressing EGFR gene after 48 hrs by MTT assay	[PMID: 22119130]
MCF7	EC₅₀	>50 μM Compound: Gefitinib	Antiproliferative activity against human ER-negative MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human ER-negative MCF7 cells after 24 hrs by MTT assay	[PMID: 25198997]
MCF7	EC₅₀	35 μM Compound: Gefitinib	Antiproliferative activity against human ER-negative MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human ER-negative MCF7 cells after 72 hrs by MTT assay	[PMID: 25198997]
MCF7	IC₅₀	10.29 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 25866240]
MCF7	IC₅₀	3.3 μM Compound: Gefitinib	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 26159483]
MCF7	IC₅₀	17.83 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
MCF7	IC₅₀	6.71 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 26346367]
MCF7	IC₅₀	13.1 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells overexpressing EGFR assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells overexpressing EGFR assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26829280]
MCF7	IC₅₀	25.37 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 27132165]
MCF7	GI₅₀	10 μM Compound: Gefitinib	Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
MCF7	GI₅₀	6.71 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells after 48 hrs in presence of 10% FBS by MTT method Antiproliferative activity against human MCF7 cells after 48 hrs in presence of 10% FBS by MTT method	[PMID: 27515719]
MCF7	GI₅₀	20.8 μM Compound: Gefitinib	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27993518]
MCF7	IC₅₀	12.05 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 28711702]
MCF7	IC₅₀	26.7 μM Compound: Gefitinib	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 29407971]
MCF7	IC₅₀	6.77 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30342958]
MCF7	GI₅₀	>30 μM Compound: Gefitinib	Growth inhibition of human MCF7 cells after 48 hrs by MTT assay Growth inhibition of human MCF7 cells after 48 hrs by MTT assay	[PMID: 30447889]
MCF7	IC₅₀	6.26 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30503938]
MCF7	IC₅₀	20.68 μM Compound: Iressa(TM)	Antiproliferative activity against human MCF7 after 18 hrs by MTT assay Antiproliferative activity against human MCF7 after 18 hrs by MTT assay	[PMID: 30826188]
MCF7	IC₅₀	23.52 μM Compound: Iressa(TM)	Antiproliferative activity against human MCF7 by MTT assay Antiproliferative activity against human MCF7 by MTT assay	[PMID: 30826188]
MCF7	IC₅₀	7.34 μM Compound: Gefitinib	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30939352]
MCF7	IC₅₀	2.97 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay	[PMID: 31431361]
MCF7	IC₅₀	>100 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 31488358]
MCF7	IC₅₀	3.3 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 33421712]
MCF7	IC₅₀	3.57 μM Compound: Gefitinib	Cytotoxicity against human MCF7 cells incubated for 2 to 4 hrs by MTT assay Cytotoxicity against human MCF7 cells incubated for 2 to 4 hrs by MTT assay	[PMID: 33771586]
MCF7	IC₅₀	13.24 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells by CCK8 assay Antiproliferative activity against human MCF7 cells by CCK8 assay	[PMID: 34922028]
MCF7	IC₅₀	0.76 μM Compound: Gefitinib	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36610250]
MCF7	IC₅₀	1.43 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth measured for 48 hrs by MTT assay	[PMID: 37875056]
MCF7	ED₅₀	0.89 μg/mL Compound: Gefitinib	Cytotoxicity against Homo sapiens (human) MCF7 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) MCF7 cells after 72 hr by MTT assay	10.1007/s00044-012-0309-2
MDA-MB-231	IC₅₀	36.61 μM Compound: ZD-1839, IRESSA	Cytotoxicity against human MDA-MB-231 cells after 96 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 96 hrs by MTT assay	[PMID: 18313807]
MDA-MB-231	IC₅₀	>10 μM Compound: Gefitinib	Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
MDA-MB-231	EC₅₀	>50 μM Compound: Gefitinib	Antiproliferative activity against human ER-positive MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human ER-positive MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 25198997]
MDA-MB-231	EC₅₀	25 μM Compound: Gefitinib	Antiproliferative activity against human ER-positive MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human ER-positive MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 25198997]
MDA-MB-231	IC₅₀	4.1 μM Compound: Gefitinib	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 26159483]
MDA-MB-231	IC₅₀	37.82 μM Compound: Gefitinib	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 27132165]
MDA-MB-231	GI₅₀	12.6 μM Compound: Gefitinib	Growth inhibition of human MDA-MB-231/ATCC cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-231/ATCC cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
MDA-MB-231	GI₅₀	14.2 μM Compound: Gefitinib	Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 28291344]
MDA-MB-231	GI₅₀	15 μM Compound: Gefitinib	Growth inhibition of human MDA-MB-231 cells Growth inhibition of human MDA-MB-231 cells	[PMID: 28291344]
MDA-MB-231	IC₅₀	28.3 μM Compound: Gefitinib	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 29656203]
MDA-MB-231	IC₅₀	8.72 μM Compound: Gefitinib	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30939352]
MDA-MB-231	IC₅₀	6.85 μM Compound: Gefitinib	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32739648]
MDA-MB-231	IC₅₀	4.1 μM Compound: Gefitinib	Antiproliferative activity against human MDA-MB-231 cells Antiproliferative activity against human MDA-MB-231 cells	[PMID: 33421712]
MDA-MB-231	IC₅₀	7.12 μM Compound: Gefitinib	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34192644]
MDA-MB-231	IC₅₀	14.52 μM Compound: Gefitinib	Antiproliferative activity against human MDA-MB-231 cells by CCK8 assay Antiproliferative activity against human MDA-MB-231 cells by CCK8 assay	[PMID: 34922028]
MDA-MB-231	IC₅₀	4.68 μM Compound: Gefitinib	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36610250]
MDA-MB-231	IC₅₀	45.31 μM Compound: Gefitinib	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay	[PMID: 38169246]
MDA-MB-468	IC₅₀	3.9 μM Compound: Gefitinib	Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 26159483]
MDA-MB-468	GI₅₀	0.01 μM Compound: Gefitinib	Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
MDA-MB-468	GI₅₀	9.7 μM Compound: Gefitinib	Cytotoxicity against gefitinib-resistant human MDA-MB-468 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against gefitinib-resistant human MDA-MB-468 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27993518]
MDA-MB-468	GI₅₀	25.5 μM Compound: Gefitinib	Growth inhibition of EGFR over-expressing human MDA-MB-468 cells after 48 hrs by MTT assay Growth inhibition of EGFR over-expressing human MDA-MB-468 cells after 48 hrs by MTT assay	[PMID: 30447889]
MDA-MB-468	IC₅₀	3.9 μM Compound: Gefitinib	Antiproliferative activity against human MDA-MB-468 cells Antiproliferative activity against human MDA-MB-468 cells	[PMID: 33421712]
MDA-MB-468	IC₅₀	2.51 μM Compound: Gefitinib	Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36610250]
MDCK	IC₅₀	1.26 μM Compound: Gefitinib	Inhibition of BCRP expressed in MDCK cells by pheophorbide A assay Inhibition of BCRP expressed in MDCK cells by pheophorbide A assay	[PMID: 19932960]
MDCK	GI₅₀	1.45 μM Compound: Gefitinib, Iressa	Cytotoxicity against MDCK cells after 72 hrs by MTT assay Cytotoxicity against MDCK cells after 72 hrs by MTT assay	[PMID: 24184213]
MDCK-II	IC₅₀	3.19 μM Compound: Gefitinib, Iressa	Inhibition of human BCRP expressed in MDCK2 cells assessed as Hoechst 33342 accumulation treated 30 mins before Hoechst 33342 addition measured up to 120 mins by fluorescence assay Inhibition of human BCRP expressed in MDCK2 cells assessed as Hoechst 33342 accumulation treated 30 mins before Hoechst 33342 addition measured up to 120 mins by fluorescence assay	[PMID: 24184213]
MDCK-II	GI₅₀	1.36 μM Compound: Gefitinib	Growth inhibition of MDCK2 cells harboring GFP-fused human ABCG2 after 72 hrs by MTT assay Growth inhibition of MDCK2 cells harboring GFP-fused human ABCG2 after 72 hrs by MTT assay	[PMID: 30390439]
MDCK-II	GI₅₀	2.1 μM Compound: Gefitinib	Growth inhibition of MDCK2 cells after 72 hrs by MTT assay Growth inhibition of MDCK2 cells after 72 hrs by MTT assay	[PMID: 30390439]
MGC-803	IC₅₀	26.19 μM Compound: Gefitinib	Antiproliferative activity against human MGC803 cells by MTT assay Antiproliferative activity against human MGC803 cells by MTT assay	[PMID: 26560049]
MGC-803	IC₅₀	8.82 μM Compound: Gefitinib	Cytotoxicity against human MGC803 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MGC803 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30939352]
MGC-803	IC₅₀	26.19 μM Compound: Gef	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32827851]
MGC-803	IC₅₀	8.19 μM Compound: Gefitinib	Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34192644]
MIA PaCa-2	IC₅₀	45.8 μM Compound: Gefitinib	Cytotoxicity against human MIAPaCa2 cells after 4 to 5 days by MTT assay Cytotoxicity against human MIAPaCa2 cells after 4 to 5 days by MTT assay	[PMID: 20466555]
MIA PaCa-2	ED₅₀	0.51 μg/mL Compound: Gefitinib	Cytotoxicity against Homo sapiens (human) MIAPaCa2 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) MIAPaCa2 cells after 72 hr by MTT assay	10.1007/s00044-012-0309-2
MKN-45	IC₅₀	12.29 μM Compound: Gefitinib	Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29496411]
MOLT-4	IC₅₀	15.02 μM Compound: ZD-1839, IRESSA	Cytotoxicity against human MOLT4 cells after 96 hrs by MTT assay Cytotoxicity against human MOLT4 cells after 96 hrs by MTT assay	[PMID: 18313807]
MOLT-4	GI₅₀	3.98 μM Compound: Gefitinib	Growth inhibition of human MOLT4 cells incubated for 48 hrs by SRB assay Growth inhibition of human MOLT4 cells incubated for 48 hrs by SRB assay	[PMID: 31023512]
MOLT-4	ED₅₀	>1 μg/mL Compound: Gefitinib	Cytotoxicity against Homo sapiens (human) MOLT4 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) MOLT4 cells after 72 hr by MTT assay	10.1007/s00044-012-0309-2
NCI-H1299	IC₅₀	3.02 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1299 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human NCI-H1299 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32739648]
NCI-H1299	IC₅₀	6.56 μM Compound: Cpd G	Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 34038131]
NCI-H1299	IC₅₀	4.05 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1299 cells expressing wild type EGFR assessed as inhibition in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human NCI-H1299 cells expressing wild type EGFR assessed as inhibition in cell viability after 72 hrs by CCK8 assay	[PMID: 34794818]
NCI-H1299	IC₅₀	40 μM Compound: Gefitinib	Cytotoxicity against human NCI-H1299 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Cytotoxicity against human NCI-H1299 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35696863]
NCI-H1299	IC₅₀	12.86 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 24 hrs by CCK-8 assay	[PMID: 36731272]
NCI-H1299	IC₅₀	16.64 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay	[PMID: 37395092]
NCI-H1650	IC₅₀	2.64 μM Compound: Gefitinib	Antiproliferative activity against human H1650 cells by CCK8 assay Antiproliferative activity against human H1650 cells by CCK8 assay	[PMID: 34922028]
NCI-H1975	IC₅₀	>10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
NCI-H1975	IC₅₀	>33 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
NCI-H1975	IC₅₀	8.26 μM Compound: 1	Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay	[PMID: 20151670]
NCI-H1975	IC₅₀	9.02 μM Compound: Gfb	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTS assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTS assay	[PMID: 22339342]
NCI-H1975	IC₅₀	10 μM Compound: Gefitinib	Cytotoxicity against human NCI-H1975 cells incubated for 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
NCI-H1975	IC₅₀	6.917 μM Compound: gefitinib	Cytotoxicity against gefitinib-resistant human NCI-H1975 cells harboring EGFR L858R/T90M double mutant assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against gefitinib-resistant human NCI-H1975 cells harboring EGFR L858R/T90M double mutant assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23668441]
NCI-H1975	IC₅₀	8.589 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant after 72 hrs by MTT assay	[PMID: 23792318]
NCI-H1975	IC₅₀	3.3 μM Compound: 1	Inhibition of EGFR L858R/T790M double mutant phosphorylation in human NCI-H1975 cells after 2 hrs by fluorescence assay Inhibition of EGFR L858R/T790M double mutant phosphorylation in human NCI-H1975 cells after 2 hrs by fluorescence assay	[PMID: 23930994]
NCI-H1975	IC₅₀	13613 nM Compound: Gefitinib	Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells expressing T790M/L858R mutation after 72 hrs by MTS assay Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells expressing T790M/L858R mutation after 72 hrs by MTS assay	[PMID: 24053674]
NCI-H1975	IC₅₀	>10 μM Compound: Gefitinib, Iressa	Cytotoxicity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant after 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant after 72 hrs by MTT assay	[PMID: 24411123]
NCI-H1975	IC₅₀	6.917 μM Compound: Iressa	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTT assay	[PMID: 24607591]
NCI-H1975	IC₅₀	10.48 μM Compound: Gefitinib	Inhibition of EGFR L858R/T790M mutant in human NCI-H1975 cells assessed as growth inhibition after 48 hrs by MTT assay Inhibition of EGFR L858R/T790M mutant in human NCI-H1975 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24900594]
NCI-H1975	IC₅₀	10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells after 48 hrs by Celltiter-Glo assay Antiproliferative activity against human NCI-H1975 cells after 48 hrs by Celltiter-Glo assay	[PMID: 25409491]
NCI-H1975	IC₅₀	14707 nM Compound: Gefitinib	Antiproliferative activity against human gefitinib-resistant NCI-H1975 cells after 48 hrs by MTT assay Antiproliferative activity against human gefitinib-resistant NCI-H1975 cells after 48 hrs by MTT assay	[PMID: 25937236]
NCI-H1975	IC₅₀	8.71 μM Compound: Gefitinib	Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells harboring EGFR T790M/L858R double mutant after 72 hrs by MTT assay Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells harboring EGFR T790M/L858R double mutant after 72 hrs by MTT assay	[PMID: 26451770]
NCI-H1975	IC₅₀	26.9 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26829280]
NCI-H1975	IC₅₀	1.23 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells over expressing EGFR after 48 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells over expressing EGFR after 48 hrs by MTT assay	[PMID: 27118497]
NCI-H1975	IC₅₀	14.38 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells expressing L858R/T790M mutant EGFR after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells expressing L858R/T790M mutant EGFR after 72 hrs by MTT assay	[PMID: 27387355]
NCI-H1975	IC₅₀	>10 μM Compound: Iressa	Cytotoxicity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27524310]
NCI-H1975	IC₅₀	10.89 μM Compound: 1	Antiproliferative activity against human NCI-H1975 cells harboring L858R/T790M double mutant after 48 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring L858R/T790M double mutant after 48 hrs by MTT assay	[PMID: 27634676]
NCI-H1975	IC₅₀	15.35 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 48 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 48 hrs by MTT assay	[PMID: 28236592]
NCI-H1975	IC₅₀	8.71 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 48 hrs by SRB assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 48 hrs by SRB assay	[PMID: 28366268]
NCI-H1975	IC₅₀	13.13 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant assessed as decrease in cell viability after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 28385595]
NCI-H1975	IC₅₀	4.691 μM Compound: 1; Iressa	Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTT assay	[PMID: 28395219]
NCI-H1975	EC₅₀	11 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as growth inhibition after 96 hrs by CellTiter-Glo assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as growth inhibition after 96 hrs by CellTiter-Glo assay	[PMID: 28603991]
NCI-H1975	IC₅₀	12.7 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTT assay	[PMID: 28711703]
NCI-H1975	EC₅₀	10.7 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR-L858R/T790M double mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR-L858R/T790M double mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay	[PMID: 28853575]
NCI-H1975	IC₅₀	12.7 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay	[PMID: 29421573]
NCI-H1975	IC₅₀	8.58 μM Compound: Gefitinib	Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29496411]
NCI-H1975	IC₅₀	7184 nM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo luminescent cell viability assay Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo luminescent cell viability assay	[PMID: 29523467]
NCI-H1975	IC₅₀	>10000 nM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay	[PMID: 29576272]
NCI-H1975	IC₅₀	10.89 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant after 72 hrs by MTT assay	[PMID: 30471829]
NCI-H1975	IC₅₀	9.1 μM Compound: 1	Growth inhibition of human NCI-H1975 cells after 72 hrs by MTT assay Growth inhibition of human NCI-H1975 cells after 72 hrs by MTT assay	[PMID: 30472599]
NCI-H1975	IC₅₀	>10000 nM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant after 72 hrs by EZ-Cytox assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant after 72 hrs by EZ-Cytox assay	[PMID: 30554954]
NCI-H1975	IC₅₀	12.7 μM Compound: ZD1839	Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTT assay	[PMID: 31202990]
NCI-H1975	IC₅₀	10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M double mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M double mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31446247]
NCI-H1975	CC₅₀	18755 nM Compound: Gefitinib	Cytotoxicity in human NCI-H1975 cells assessed as reduction in cell viability incubated for 96 hrs by MTS method Cytotoxicity in human NCI-H1975 cells assessed as reduction in cell viability incubated for 96 hrs by MTS method	[PMID: 31560541]
NCI-H1975	IC₅₀	>10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M/C797S mutant incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M/C797S mutant incubated for 72 hrs by MTS assay	[PMID: 31718182]
NCI-H1975	IC₅₀	>10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTS assay	[PMID: 31718182]
NCI-H1975	IC₅₀	6.5 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells measured after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells measured after 72 hrs by MTT assay	[PMID: 31757525]
NCI-H1975	IC₅₀	78.7 μM Compound: Gefitinib	Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells measured after 72 hrs by MTT assay Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells measured after 72 hrs by MTT assay	[PMID: 31757525]
NCI-H1975	IC₅₀	44.6 μM Compound: 1	Antiproliferative activity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant assessed as inhibition of cell growth by MTT assay	[PMID: 31869655]
NCI-H1975	IC₅₀	>10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32139324]
NCI-H1975	IC₅₀	4.81 μM Compound: Gefitinib	Growth inhibition of human NCI-H1975 cells incubated for 5 days by SRB assay Growth inhibition of human NCI-H1975 cells incubated for 5 days by SRB assay	[PMID: 32145644]
NCI-H1975	IC₅₀	17.79 μM Compound: Gefitinib	Antiproliferative activity against human H1975 cells harboring EGFR L858R/T790M double mutant assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human H1975 cells harboring EGFR L858R/T790M double mutant assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32402937]
NCI-H1975	IC₅₀	3102 nM Compound: 10	Growth inhibition of human NCI-H1975 cells harboring EGFR L858R/T790M double mutant Growth inhibition of human NCI-H1975 cells harboring EGFR L858R/T790M double mutant	[PMID: 32432477]
NCI-H1975	IC₅₀	10.89 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32739648]
NCI-H1975	IC₅₀	10.78 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33640672]
NCI-H1975	IC₅₀	9.2 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34192644]
NCI-H1975	IC₅₀	1.71 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells expressing EGFR T790M/L858R mutant assessed as inhibition in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1975 cells expressing EGFR T790M/L858R mutant assessed as inhibition in cell viability after 72 hrs by CCK-8 assay	[PMID: 34794818]
NCI-H1975	IC₅₀	13.44 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells expressing EGFR T790M mutant assessed as inhibition of cell growth Antiproliferative activity against human NCI-H1975 cells expressing EGFR T790M mutant assessed as inhibition of cell growth	[PMID: 35728507]
NCI-H1975	IC₅₀	25.56 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 24 hrs by CCK-8 assay	[PMID: 36731272]
NCI-H1975	IC₅₀	32.15 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay	[PMID: 37395092]
NCI-H1975	IC₅₀	10.1 μM Compound: Gefitinib	Anticancer activity against human NCI-H1975 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Anticancer activity against human NCI-H1975 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 37952262]
NCI-H1975	IC₅₀	>10 μM Compound: 1	Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by CCK8 assay	[PMID: 38564826]
NCI-H1975	IC₅₀	18.19 μM Compound: Gefitinib	Cytotoxicity against human NCI-H1975 cells expressing EGFR kinase L858R/T790M double mutant after 72 hrs by MTS assay Cytotoxicity against human NCI-H1975 cells expressing EGFR kinase L858R/T790M double mutant after 72 hrs by MTS assay	10.1039/C2MD20078C
NCI-H1975	IC₅₀	11.39 μM Compound: Gefitinib	Cytotoxicity against gefitinib-resistant human NCI-H1975 cells expressing EGFR L858R/T790M double mutant assessed as growth inhibition incubated for 1 hr prior to EGF challenge measured after 72 hrs by luciferase reporter gene assay Cytotoxicity against gefitinib-resistant human NCI-H1975 cells expressing EGFR L858R/T790M double mutant assessed as growth inhibition incubated for 1 hr prior to EGF challenge measured after 72 hrs by luciferase reporter gene assay	10.1039/C3MD00118K
NCI-H1975	IC₅₀	13.98 μM Compound: Gefitinib	Inhibition of EGFR L858R/T790M mutant in human NCI-H1975 cells assessed as inhibition of EGF-mediated autophosphorylation incubated for 30 mins prior to EGF challenge by cytoblot assay Inhibition of EGFR L858R/T790M mutant in human NCI-H1975 cells assessed as inhibition of EGF-mediated autophosphorylation incubated for 30 mins prior to EGF challenge by cytoblot assay	10.1039/C3MD00118K
NCI-H1993	IC₅₀	0.1 μM Compound: Gef	Antiproliferative activity against human NCI-H1993 cells after 3 days by SRB assay Antiproliferative activity against human NCI-H1993 cells after 3 days by SRB assay	[PMID: 21916433]
NCI-H1993	IC₅₀	20 μM Compound: Gef	Antiproliferative activity against gefitinib resistant human NCI-H1993 cells after 3 days by SRB assay Antiproliferative activity against gefitinib resistant human NCI-H1993 cells after 3 days by SRB assay	[PMID: 21916433]
NCI-H226	GI₅₀	15.9 μM Compound: Gefitinib	Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
NCI-H23	GI₅₀	15.9 μM Compound: Gefitinib	Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
NCI-H23	IC₅₀	1.02 μM Compound: Gefitinib	Cytotoxicity against human NCI-H23 cells assessed as reduction in cell viability after 46 hrs by MTT assay Cytotoxicity against human NCI-H23 cells assessed as reduction in cell viability after 46 hrs by MTT assay	[PMID: 29138027]
NCI-H292	IC₅₀	0.02 μM Compound: Gef	Antiproliferative activity against human NCI-H292 cells after 3 days by SRB assay Antiproliferative activity against human NCI-H292 cells after 3 days by SRB assay	[PMID: 21916433]
NCI-H292	IC₅₀	0.41 μM Compound: Gef	Antiproliferative activity against gefitinib resistant human NCI-H292 cells after 3 days by SRB assay Antiproliferative activity against gefitinib resistant human NCI-H292 cells after 3 days by SRB assay	[PMID: 21916433]
NCI-H292	IC₅₀	0.12 μM Compound: Gefitinib	Cytotoxicity against human NCI-H292 cells incubated for 72 hrs by MTT assay Cytotoxicity against human NCI-H292 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
NCI-H292	IC₅₀	0.19 μM Compound: Gefitinib	Cytotoxicity against human NCI-H292 cells after 72 hrs by SRB assay Cytotoxicity against human NCI-H292 cells after 72 hrs by SRB assay	[PMID: 25215856]
NCI-H322M	GI₅₀	0.08 μM Compound: Gefitinib	Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
NCI-H322M	GI₅₀	0.08 μM Compound: Gefitinib	Growth inhibition of human NCI-H322M cells incubated for 48 hrs by SRB assay Growth inhibition of human NCI-H322M cells incubated for 48 hrs by SRB assay	[PMID: 31023512]
NCI-H3255	IC₅₀	>10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant transfected with EGFR Del L747_S752,P753S/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant transfected with EGFR Del L747_S752,P753S/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
NCI-H3255	IC₅₀	>10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant transfected with EGFR L858R/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant transfected with EGFR L858R/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
NCI-H3255	IC₅₀	>10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant transfected with EGFR WT/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant transfected with EGFR WT/T790M mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
NCI-H3255	IC₅₀	0.071 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant transfected with GFP assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant transfected with GFP assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
NCI-H3255	IC₅₀	0.075 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
NCI-H3255	IC₅₀	22 nM Compound: Gefitinib	Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
NCI-H3255	IC₅₀	40 nM Compound: Gefitinib	Antiproliferative activity against human NCI-H3255 cells expressing EGFR L858R mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H3255 cells expressing EGFR L858R mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 35728507]
NCI-H3255	IC₅₀	0.863 μM Compound: Gefitinib	Growth inhibition of human NCI-H3255 cells harbouring EGFR L858R mutant incubated for 72 hrs by CCK8 assay Growth inhibition of human NCI-H3255 cells harbouring EGFR L858R mutant incubated for 72 hrs by CCK8 assay	[PMID: 35880853]
NCI-H3255	IC₅₀	11 nM Compound: 1	Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo luminescent assay Antiproliferative activity against human NCI-H3255 cells harboring EGFR L858R mutant assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo luminescent assay	[PMID: 37934858]
NCI-H3255	IC₅₀	0.007 μM Compound: 1	Antiproliferative activity against human NCI-H3255 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human NCI-H3255 cells incubated for 72 hrs by CCK8 assay	[PMID: 38564826]
NCI-H358	IC₅₀	14.66 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H358 cells assessed as viable cells after 48 hrs by CCK8 assay Antiproliferative activity against human NCI-H358 cells assessed as viable cells after 48 hrs by CCK8 assay	[PMID: 26879314]
NCI-H358	IC₅₀	5.68 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H358 cells assessed as reduction in cell viability after 48 hrs by cck8 assay Antiproliferative activity against human NCI-H358 cells assessed as reduction in cell viability after 48 hrs by cck8 assay	[PMID: 27234887]
NCI-H441	IC₅₀	>10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H441 cells harboring K-ras G12V mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H441 cells harboring K-ras G12V mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
NCI-H460	IC₅₀	5.59 μM Compound: Iressa	Cytotoxicity against human H460 cells after 72 hrs by MTT assay Cytotoxicity against human H460 cells after 72 hrs by MTT assay	[PMID: 22727449]
NCI-H460	IC₅₀	7.6 μM Compound: Cefitinib	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability	[PMID: 25105722]
NCI-H460	IC₅₀	21 μM Compound: Gefitinib	Cytotoxicity against human H460 cells after 72 hrs by SRB assay Cytotoxicity against human H460 cells after 72 hrs by SRB assay	[PMID: 25215856]
NCI-H460	GI₅₀	6.31 μM Compound: Gefitinib	Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
NCI-H460	GI₅₀	6.31 μM Compound: Gefitinib	Growth inhibition of human NCI-H460 cells incubated for 48 hrs by SRB assay Growth inhibition of human NCI-H460 cells incubated for 48 hrs by SRB assay	[PMID: 31023512]
NCI-H460	IC₅₀	3.02 μM Compound: Gefitinib	Antiproliferative activity against human H460 cells by CCK8 assay Antiproliferative activity against human H460 cells by CCK8 assay	[PMID: 34922028]
NCI-H522	GI₅₀	6.31 μM Compound: Gefitinib	Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
NCI-H661	IC₅₀	31.06 μM Compound: Gefitinib	Cytotoxicity against human NCI-H661 cells after 4 to 5 days by MTT assay Cytotoxicity against human NCI-H661 cells after 4 to 5 days by MTT assay	[PMID: 20466555]
NCI-N87	IC₅₀	1 μM Compound: Gefitinib, Iressa	Cytotoxicity against human NCI-N87 cells expressing HER2 after 72 hrs by MTT assay Cytotoxicity against human NCI-N87 cells expressing HER2 after 72 hrs by MTT assay	[PMID: 24411123]
NCI-N87	IC₅₀	1 μM Compound: Iressa	Cytotoxicity against human NCI-N87 cells overexpressing HER2 assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human NCI-N87 cells overexpressing HER2 assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27524310]
NCI-N87	IC₅₀	1 μM Compound: Gefitinib	Antiproliferative activity against human NCI-N87 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human NCI-N87 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32139324]
NIH3T3	IC₅₀	14.4 nM Compound: gefitinib	Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells Inhibition of EGF stimulated human erbB1 autophosphorylation in NIH3T3 cells	[PMID: 16480284]
NIH3T3	IC₅₀	0.54 μM Compound: Iressa	Growth inhibition of mouse NIH/3T3 cells expressing erB2 gene Growth inhibition of mouse NIH/3T3 cells expressing erB2 gene	[PMID: 19665377]
Non-small cell lung cancer cell line	GI₅₀	7.81 μM Compound: Gefitinib	Growth inhibition of human Non-small cell lung cancer cell line incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Non-small cell lung cancer cell line incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
OVCAR-3	GI₅₀	5.01 μM Compound: Gefitinib	Growth inhibition of human OVCAR-3 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR-3 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
OVCAR-4	GI₅₀	7.94 μM Compound: Gefitinib	Growth inhibition of human OVCAR-4 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR-4 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
OVCAR-8	GI₅₀	10 μM Compound: Gefitinib	Growth inhibition of human OVCAR-8 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR-8 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
PANC-1	IC₅₀	69.32 μM Compound: Gefitinib	Antiproliferative activity against human PANC1 cells after 48 hrs by MTT assay Antiproliferative activity against human PANC1 cells after 48 hrs by MTT assay	[PMID: 20304537]
PANC-1	IC₅₀	40.42 μM Compound: Gefitinib	Cytotoxicity against human PANC1 cells after 4 to 5 days by MTT assay Cytotoxicity against human PANC1 cells after 4 to 5 days by MTT assay	[PMID: 20466555]
Panel breast (Carcinoma cell lines)	GI₅₀	7.81 μM Compound: Gefitinib	Growth inhibition of human Panel breast (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel breast (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel CNS (Carcinoma cell lines)	GI₅₀	8.14 μM Compound: Gefitinib	Growth inhibition of human Panel CNS (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel CNS (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel colon (Carcinoma cell lines)	GI₅₀	7.02 μM Compound: Gefitinib	Growth inhibition of human Panel colon (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel colon (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel leukemia (Carcinoma cell lines)	GI₅₀	3.54 μM Compound: Gefitinib	Growth inhibition of human Panel leukemia (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel leukemia (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel melanoma (Carcinoma cell lines)	GI₅₀	5.28 μM Compound: Gefitinib	Growth inhibition of human Panel melanoma (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel melanoma (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel NCI-60 (60 carcinoma cell lines)	GI₅₀	3.24 μM Compound: Gefitinib	Growth inhibition of human Panel NCI-60 (60 carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel NCI-60 (60 carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel NCI-60 (60 carcinoma cell lines)	GI₅₀	3.24 μM Compound: Gefitinib	Anticancer activity against human Panel NCI-60 (60 carcinoma cell lines) cells assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay Anticancer activity against human Panel NCI-60 (60 carcinoma cell lines) cells assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay	[PMID: 31881454]
Panel ovarian (Carcinoma cell lines)	GI₅₀	6.63 μM Compound: Gefitinib	Growth inhibition of human Panel ovarian (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel ovarian (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel prostate (Carcinoma cell lines)	GI₅₀	1.65 μM Compound: Gefitinib	Growth inhibition of human Panel prostate (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel prostate (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel renal (Carcinoma cell lines)	GI₅₀	2.67 μM Compound: Gefitinib	Growth inhibition of human Panel renal (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel renal (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
PC-3	IC₅₀	15.1 μM Compound: ZD-1839, IRESSA	Cytotoxicity against human PC3 cells after 96 hrs by MTT assay Cytotoxicity against human PC3 cells after 96 hrs by MTT assay	[PMID: 18313807]
PC-3	IC₅₀	22.86 μM Compound: Gefitinib	Cytotoxicity against human PC3 cells after 4 to 5 days by MTT assay Cytotoxicity against human PC3 cells after 4 to 5 days by MTT assay	[PMID: 20466555]
PC-3	IC₅₀	7.4 μM Compound: ZD1839, Iressa	Antiproliferative activity against human PC3 cells at 10 uM after 72 hrs by MTS assay Antiproliferative activity against human PC3 cells at 10 uM after 72 hrs by MTS assay	[PMID: 21353546]
PC-3	GI₅₀	0.8 μM Compound: Gefitinib	Growth inhibition of human PC-3 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human PC-3 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
PC-3	IC₅₀	7.99 μM Compound: Gefitinib	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30939352]
PC-3	IC₅₀	5.3 μM Compound: Gefitinib	Growth inhibition of human PC3 cells after 5 days by SRB assay Growth inhibition of human PC3 cells after 5 days by SRB assay	[PMID: 32484346]
PC-3	IC₅₀	8.92 μM Compound: Gefitinib	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34192644]
PC-3	IC₅₀	1.37 μM Compound: Gefitinib	Synergistic antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs in presence of BI-3406 by MTT assay Synergistic antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs in presence of BI-3406 by MTT assay	[PMID: 38630077]
PC-3	IC₅₀	9.64 μM Compound: Gefitinib	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38630077]
PC-3	IC₅₀	2.8 μM Compound: Gefitinib	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	10.1007/s00044-013-0734-x
PC-3	IC₅₀	7.4 μM Compound: Iressa, Gefitinib, ZD1839	Antiproliferative activity against human PC3 cells at 10 uM by MTS assay Antiproliferative activity against human PC3 cells at 10 uM by MTS assay	10.1039/C0MD00183J
PC-9	IC₅₀	0.023 μM Compound: Gefitinib	Antiproliferative activity against human PC-9 cells harboring EGFR Del E746_A750 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human PC-9 cells harboring EGFR Del E746_A750 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 18089823]
PC-9	IC₅₀	17 nM Compound: Gefitinib	Antiproliferative activity against human PC-9 cells harboring EGFR Del E746_A750 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay Antiproliferative activity against human PC-9 cells harboring EGFR Del E746_A750 mutant assessed as inhibition of cell growth incubated for 72 hrs by MTS assay	[PMID: 20033049]
PC-9	EC₅₀	0.017 μM Compound: Iressa	Antiproliferative activity against EGFR-deficient human PC9 cells Antiproliferative activity against EGFR-deficient human PC9 cells	[PMID: 21208802]
PC-9	EC₅₀	7 μM Compound: Iressa	Antiproliferative activity against growth-resistant human PC9 cells expressing EGFR E746_A750/T790M mutant Antiproliferative activity against growth-resistant human PC9 cells expressing EGFR E746_A750/T790M mutant	[PMID: 21208802]
PC-9	IC₅₀	0.014 μM Compound: Gefitinib	Cytotoxicity against human PC9 cells incubated for 72 hrs by MTT assay Cytotoxicity against human PC9 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
PC-9	IC₅₀	0.0087 μM Compound: 1	Inhibition of EGFR exon 19 deletion activating mutant phosphorylation in human PC9 cells after 2 hrs by fluorescence assay Inhibition of EGFR exon 19 deletion activating mutant phosphorylation in human PC9 cells after 2 hrs by fluorescence assay	[PMID: 23930994]
PC-9	IC₅₀	6.2 nM Compound: Gefitinib	Inhibition of EGFR exon19 deletion mutant phosphorylation in human PC9 cells Inhibition of EGFR exon19 deletion mutant phosphorylation in human PC9 cells	[PMID: 26313252]
PC-9	IC₅₀	0.063 μM Compound: Gefitinib	Antiproliferative activity against gefitinib-sensitive human PC9 cells assessed as cell viability after 72 hrs by cell titer-glo luminescence assay Antiproliferative activity against gefitinib-sensitive human PC9 cells assessed as cell viability after 72 hrs by cell titer-glo luminescence assay	[PMID: 27288180]
PC-9	IC₅₀	>10000 nM Compound: Gefitinib	Anticancer activity against human PC-9 cells harboring C797S/T790M/del19 mutant assessed as inhibition of cell viability incubated for 72 hrs by CellTiter-Glo assay Anticancer activity against human PC-9 cells harboring C797S/T790M/del19 mutant assessed as inhibition of cell viability incubated for 72 hrs by CellTiter-Glo assay	[PMID: 28287083]
PC-9	IC₅₀	14684 nM Compound: Gefitinib	Anticancer activity against human PC-9 cells harboring T790M/del19 mutant assessed as inhibition of cell viability incubated for 72 hrs by CellTiter-Glo assay Anticancer activity against human PC-9 cells harboring T790M/del19 mutant assessed as inhibition of cell viability incubated for 72 hrs by CellTiter-Glo assay	[PMID: 28287083]
PC-9	IC₅₀	16.38 nM Compound: Gefitinib	Anticancer activity against human PC-9 cells harboring del19 mutant assessed as inhibition of cell viability incubated for 72 hrs by CellTiter-Glo assay Anticancer activity against human PC-9 cells harboring del19 mutant assessed as inhibition of cell viability incubated for 72 hrs by CellTiter-Glo assay	[PMID: 28287083]
PC-9	IC₅₀	6.1 nM Compound: Gefitinib	Antiproliferative activity against human PC9 cells harboring EGFR exon-19 del mutant after 72 hrs by EZ-Cytox assay Antiproliferative activity against human PC9 cells harboring EGFR exon-19 del mutant after 72 hrs by EZ-Cytox assay	[PMID: 30554954]
PC-9	IC₅₀	0.1 μM Compound: Gefitinib	Antiproliferative activity against human PC9 cells harbouring EGFR delE746-A750 mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human PC9 cells harbouring EGFR delE746-A750 mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31446247]
PC-9	IC₅₀	0.017 μM Compound: Gefitinib	Growth inhibition of human PC-9 cells incubated for 5 days by SRB assay Growth inhibition of human PC-9 cells incubated for 5 days by SRB assay	[PMID: 32145644]
PC-9	IC₅₀	31.32 μM Compound: Gefitinib	Antiproliferative activity against human PC9 cells harboring EGFRdel19 mutant assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human PC9 cells harboring EGFRdel19 mutant assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32402937]
PC-9	IC₅₀	0.1 μM Compound: Gefitinib	Antiproliferative activity against human PC-9 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human PC-9 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 32739648]
PC-9	IC₅₀	0.463 μM Compound: 1	Antiproliferative activity against human PC-9 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human PC-9 cells incubated for 72 hrs by CCK8 assay	[PMID: 38564826]
PLC-PRF-5	IC₅₀	4 μM Compound: Gefitinib	Cytotoxicity against human PLC/PRF/5 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human PLC/PRF/5 cells assessed as reduction in cell viability by MTT assay	[PMID: 31013087]
RXF 393	GI₅₀	5.01 μM Compound: Gefitinib	Growth inhibition of human RXF 393 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human RXF 393 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Sf21	IC₅₀	12 nM Compound: Gefitinib	Inhibition of human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate Inhibition of human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate	[PMID: 30554954]
Sf21	IC₅₀	151 nM Compound: Gefitinib	Inhibition of human C-terminal His6-tagged ERBB2 (676 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate Inhibition of human C-terminal His6-tagged ERBB2 (676 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate	[PMID: 30554954]
Sf21	IC₅₀	460 nM Compound: Gefitinib	Inhibition of human N-terminal GST-tagged EGFR T790M/L858R double mutant (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate Inhibition of human N-terminal GST-tagged EGFR T790M/L858R double mutant (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate	[PMID: 30554954]
SF-295	GI₅₀	2 μM Compound: Gefitinib	Growth inhibition of human SF-295 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SF-295 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Sf9	IC₅₀	0.4 μM Compound: Gefitinib (ZD1839)	TP_TRANSPORTER: efflux of Hoechst33342 in BCRP-expressing Sf9 cells TP_TRANSPORTER: efflux of Hoechst33342 in BCRP-expressing Sf9 cells	[PMID: 15155841]
Sf9	IC₅₀	0.033 μM Compound: Iressa	Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry	[PMID: 20056425]
Sf9	IC₅₀	0.033 μM Compound: Iressa	Inhibition of human EGFR autophosphorylation expressed in Sf9 cells DELFIA assay Inhibition of human EGFR autophosphorylation expressed in Sf9 cells DELFIA assay	[PMID: 20304535]
Sf9	IC₅₀	0.02 μM Compound: Gefitinib, Iressa	Inhibition of recombinant His6-tagged EGFR expressed in baculovirus infected insect Sf9 cells using ATP as substrate and cofactor MgCl2 after 2 hrs by DELFIA/Time-resolved fluorometric analysis Inhibition of recombinant His6-tagged EGFR expressed in baculovirus infected insect Sf9 cells using ATP as substrate and cofactor MgCl2 after 2 hrs by DELFIA/Time-resolved fluorometric analysis	[PMID: 22119130]
Sf9	IC₅₀	15 nM Compound: Gefitinib	Inhibition of human GST-tagged EGFR L834R mutant expressed in Sf9 cells by luminescence assay Inhibition of human GST-tagged EGFR L834R mutant expressed in Sf9 cells by luminescence assay	[PMID: 23611691]
Sf9	IC₅₀	33 nM Compound: Gefitinib	Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay	[PMID: 23611691]
Sf9	IC₅₀	<0.001 μM Compound: gefitinib	Inhibition of EGFR L858R mutant (unknown origin) expressed in Sf9 cells pre-incubated for 60 mins before substrate and ATP addition by homogeneous time-resolved FRET assay Inhibition of EGFR L858R mutant (unknown origin) expressed in Sf9 cells pre-incubated for 60 mins before substrate and ATP addition by homogeneous time-resolved FRET assay	[PMID: 26275028]
Sf9	IC₅₀	<0.001 μM Compound: gefitinib	Inhibition of wild type EGFR (unknown origin) expressed in Sf9 cells pre-incubated for 30 mins before substrate and ATP addition by homogeneous time-resolved FRET assay Inhibition of wild type EGFR (unknown origin) expressed in Sf9 cells pre-incubated for 30 mins before substrate and ATP addition by homogeneous time-resolved FRET assay	[PMID: 26275028]
Sf9	IC₅₀	0.1 μM Compound: gefitinib	Inhibition of EGFR L858R/T790M mutant (unknown origin) expressed in Sf9 cells pre-incubated for 60 mins before substrate and ATP addition by homogeneous time-resolved FRET assay Inhibition of EGFR L858R/T790M mutant (unknown origin) expressed in Sf9 cells pre-incubated for 60 mins before substrate and ATP addition by homogeneous time-resolved FRET assay	[PMID: 26275028]
Sf9	IC₅₀	>1 μM Compound: 1	Irreversible inhibition of human recombinant GST-tagged JAK3 expressed in baculovirus infected Sf9 insect cells assessed as reduction in polyglutamic acid-tyrosine phosphorylation after 30 mins by ELISA Irreversible inhibition of human recombinant GST-tagged JAK3 expressed in baculovirus infected Sf9 insect cells assessed as reduction in polyglutamic acid-tyrosine phosphorylation after 30 mins by ELISA	[PMID: 27491023]
Sf9	IC₅₀	0.003 μM Compound: 1	Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA	[PMID: 27491023]
Sf9	IC₅₀	0.343 μM Compound: 1	Irreversible inhibition of GST-tagged ERBB2 (unknown origin) (Ile-675 to Val-1256 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA Irreversible inhibition of GST-tagged ERBB2 (unknown origin) (Ile-675 to Val-1256 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA	[PMID: 27491023]
Sf9	IC₅₀	0.476 μM Compound: 1	Irreversible inhibition of GST-tagged ERBB4 (unknown origin) (Gly-259 to Gly-690 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA Irreversible inhibition of GST-tagged ERBB4 (unknown origin) (Gly-259 to Gly-690 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA	[PMID: 27491023]
Sf9	IC₅₀	15.5 nM Compound: Gefitinib	Inhibition of wild-type human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay Inhibition of wild-type human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay	[PMID: 30471829]
Sf9	IC₅₀	823.3 nM Compound: Gefitinib	Inhibition of human N-terminal GST-tagged EGFR T790M/L858R double mutant (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay Inhibition of human N-terminal GST-tagged EGFR T790M/L858R double mutant (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay	[PMID: 30471829]
Sf9	IC₅₀	0.39 μM Compound: Gefitinib	Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay	[PMID: 31718182]
Sf9	IC₅₀	3.17 μM Compound: Gefitinib	Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M/C797S mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo ki Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M/C797S mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo ki	[PMID: 31718182]
Sf9	IC₅₀	4.99 μM Compound: Gefitinib	Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M double mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo k Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M double mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo k	[PMID: 31718182]
SGC-7901	IC₅₀	10.26 μM Compound: Iressa	Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay	[PMID: 22727449]
SGC-7901	IC₅₀	29.01 μM Compound: Gefitinib	Cytotoxicity against human SGC-7901 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SGC-7901 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32866757]
SH-SY5Y	IC₅₀	18.21 μM Compound: 2	Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay	[PMID: 23871909]
SH-SY5Y	IC₅₀	18.21 μM Compound: Gefitinib	Antiproliferative activity against human SH-SY5Y cells after 72 hrs by MTT assay Antiproliferative activity against human SH-SY5Y cells after 72 hrs by MTT assay	[PMID: 28711702]
SH-SY5Y	IC₅₀	18.216 μM Compound: Gefitinib	Antiproliferative activity against human SH-SY5Y cells incubated for 72 hrs by MTT assay Antiproliferative activity against human SH-SY5Y cells incubated for 72 hrs by MTT assay	[PMID: 31488358]
SK-BR-3	IC₅₀	0.174 μg/mL Compound: 1 iressa	Inhibition of SKBR-3 cell proliferation Inhibition of SKBR-3 cell proliferation	[PMID: 12270171]
SK-BR-3	IC₅₀	4.92 μM Compound: Gefitinib	Antiproliferative activity against human SK-BR-3 cells after 72 hrs by MTT assay Antiproliferative activity against human SK-BR-3 cells after 72 hrs by MTT assay	[PMID: 27132165]
SK-BR-3	IC₅₀	2518 nM Compound: Gefitinib	Antiproliferative activity against HER2-dependant human SKBR3 cells after 72 hrs by EZ-Cytox assay Antiproliferative activity against HER2-dependant human SKBR3 cells after 72 hrs by EZ-Cytox assay	[PMID: 30554954]
SK-BR-3	IC₅₀	5.36 μM Compound: Gefitinib	Cytotoxicity against human SKBR3 cells expressing wild type EGFR assessed as growth inhibition incubated for 1 hr prior to EGF challenge measured after 72 hrs by luciferase reporter gene assay Cytotoxicity against human SKBR3 cells expressing wild type EGFR assessed as growth inhibition incubated for 1 hr prior to EGF challenge measured after 72 hrs by luciferase reporter gene assay	10.1039/C3MD00118K
SK-HEP1	IC₅₀	10.1 μM Compound: Gefitinib	Cytotoxicity against human SKHEP1 cells after 72 hrs by SRB assay Cytotoxicity against human SKHEP1 cells after 72 hrs by SRB assay	[PMID: 29407971]
SK-MEL-28	IC₅₀	>20 μM Compound: 3	Antiproliferative activity against human SK-MEL-28 cells harboring BRAF V600E mutant after 68 hrs by MTS assay Antiproliferative activity against human SK-MEL-28 cells harboring BRAF V600E mutant after 68 hrs by MTS assay	[PMID: 24588073]
SK-MEL-28	GI₅₀	0.32 μM Compound: Gefitinib	Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
SK-OV-3	IC₅₀	24.5 μM Compound: Gefitinib	Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32739648]
SMMC-7721	IC₅₀	33.12 μM Compound: Gefitinib	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 20304537]
SMMC-7721	IC₅₀	4.16 μM Compound: Gefitinib	Antiproliferative activity against human SMMC7721 cells over expressing EGFR after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells over expressing EGFR after 48 hrs by MTT assay	[PMID: 27118497]
SMMC-7721	IC₅₀	9.2 μM Compound: Gefitinib	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay	[PMID: 31013087]
SNB-75	GI₅₀	6.31 μM Compound: Gefitinib	Growth inhibition of human SNB-75 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SNB-75 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
SNU-638	IC₅₀	7.56 μM Compound: Gefitinib	Cytotoxicity against human SNU638 cells after 72 hrs by SRB assay Cytotoxicity against human SNU638 cells after 72 hrs by SRB assay	[PMID: 29407971]
SR	GI₅₀	3.16 μM Compound: Gefitinib	Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
SW480	IC₅₀	12.5 μM Compound: Gefitinib	Antiproliferative activity against human SW480 cells harboring wild type EGFR after 72 hrs by MTT assay Antiproliferative activity against human SW480 cells harboring wild type EGFR after 72 hrs by MTT assay	[PMID: 28711703]
SW480	IC₅₀	12.5 μM Compound: Gefitinib	Antiproliferative activity against human SW480 cells harboring wild type EGFR after 72 hrs by MTT assay Antiproliferative activity against human SW480 cells harboring wild type EGFR after 72 hrs by MTT assay	[PMID: 29421573]
SW480	IC₅₀	12.5 μM Compound: ZD1839	Antiproliferative activity against human SW480 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human SW480 cells incubated for 72 hrs by MTT assay	[PMID: 31202990]
SW-620	IC₅₀	>5 μg/mL Compound: 1 iressa	Inhibition of SW-620 cell proliferation Inhibition of SW-620 cell proliferation	[PMID: 12270171]
SW-620	IC₅₀	>10 μM Compound: 1	Cytotoxicity against human SW620 cells after 72 hrs by MTT assay Cytotoxicity against human SW620 cells after 72 hrs by MTT assay	[PMID: 20151670]
SW-620	IC₅₀	28.2 μM Compound: Gefitinib	Cytotoxicity against human SW620 cells after 48 hrs by CellTiter-Glo assay Cytotoxicity against human SW620 cells after 48 hrs by CellTiter-Glo assay	[PMID: 24900594]
T-24	IC₅₀	599 nM Compound: gefitinib	Inhibition of ligand stimulated erbB2 autophosphorylation in T24 NIH cells Inhibition of ligand stimulated erbB2 autophosphorylation in T24 NIH cells	[PMID: 16480284]
T-24	IC₅₀	14.6 μM Compound: Gef	Antiproliferative activity against human T-24 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Antiproliferative activity against human T-24 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 32827851]
T47D	IC₅₀	3.47 μM Compound: Gefitinib	Cytotoxicity against human T47D cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human T47D cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36610250]
TK-10	GI₅₀	0.1 μM Compound: Gefitinib	Growth inhibition of human TK-10 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human TK-10 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
U-251	IC₅₀	10.8 μM Compound: Cefitinib	Cytotoxicity against human U251 cells assessed as reduction in cell viability Cytotoxicity against human U251 cells assessed as reduction in cell viability	[PMID: 25105722]
U-251	GI₅₀	10 μM Compound: Gefitinib	Growth inhibition of human U-251 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human U-251 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
U-251	IC₅₀	10.88 μM Compound: Gefitinib	Antiproliferative activity against human U-251 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human U-251 cells incubated for 72 hrs by MTT assay	[PMID: 38739112]
U-87MG ATCC	IC₅₀	8.2 μM Compound: Gefitinib	Antiproliferative activity against human U87 cells after 48 hrs by MTT assay Antiproliferative activity against human U87 cells after 48 hrs by MTT assay	[PMID: 28462838]
U-87MG ATCC	IC₅₀	22.4 μM Compound: 1	Antiproliferative activity against human U-87MG cells harboring wild type EGFR assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human U-87MG cells harboring wild type EGFR assessed as inhibition of cell growth by MTT assay	[PMID: 31869655]
U-87MG ATCC	IC₅₀	10.35 μM Compound: Gefitinib	Antiproliferative activity against human U-87 MG cells incubated for 72 hrs by MTT assay Antiproliferative activity against human U-87 MG cells incubated for 72 hrs by MTT assay	[PMID: 38739112]
UACC-257	GI₅₀	6.31 μM Compound: Gefitinib	Growth inhibition of human UACC-257 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human UACC-257 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
UACC-62	GI₅₀	5.01 μM Compound: Gefitinib	Growth inhibition of human UACC-62 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human UACC-62 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
UO-31	GI₅₀	1.26 μM Compound: Gefitinib	Growth inhibition of human UO-31 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human UO-31 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Vero	IC₅₀	>100 μM Compound: Gefitinib	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	[PMID: 28927795]
Vero	IC₅₀	>10 μM Compound: 1	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30655941]
WM 266-4	IC₅₀	17.42 μM Compound: Gefitinib	Antiproliferative activity against human WM266.4 cells assessed as inhibition of cell viability after 48 hrs by MTS assay Antiproliferative activity against human WM266.4 cells assessed as inhibition of cell viability after 48 hrs by MTS assay	[PMID: 31494469]

In Vitro

Gefitinib (GMP) abolishes the effect of EGF-induced dedifferentiation of astrocytes into astrocyte precursor cells (APCs)^[2].
Gefitinib (3 μM) can produce a subgroup of EGFR-mutant NSCLC cell lines (Gefitinib-resistant cells) that undergo cellular reprogramming, such as HCC827 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 184475-35-2
Appearance Solid
Molecular Weight 446.90
Formula C₂₂H₂₄ClFN₄O₃
Color White to off-white
SMILES

ClC1=C(C=CC(NC2=NC=NC3=C2C=C(C(OC)=C3)OCCCN4CCOCC4)=C1)F
Synonyms

ZD1839 (GMP)
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (271 KB)
SDS (923 KB)
- English - EN (923 KB)
- Français - FR (923 KB)
- Deutsch - DE (923 KB)
- Norwegian - NO (923 KB)
- Español - ES (923 KB)
- Swedish - SV (923 KB)
- Italian - IT (923 KB)
- Korean - KR (923 KB)
- Portuguese - PT (923 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Wakeling AE, et al. ZD1839: an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002 Oct 15;62(20):5749-54. [Content Brief]

[2]. Liu X, Li C, et al. EGF signaling promotes the lineage conversion of astrocytes into oligodendrocytes. Mol Med. 2022 May 4;28(1):50. [Content Brief]

[3]. Ware KE, et al. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis. 2013 Mar 25;2(3):e39. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Gefitinib (GMP)

All EGFR Isoforms

Biological Activity

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

Gefitinib (GMP) Related Classifications

HY-50895G Related Classifications